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ABSTRACT
The present investigation has been undertaken to study the wound healing properties 
of ethyl acetate and aqueous extracts of Simarouba glauca. The plant Simarouba 
glauca has a long history in herbal medicine in many countries. Experiments were 
conducted following standard procedures. Both extracts were evaluated for their in 
vitro anti oxidant, antimicrobial and cytotoxic properties. The EASG and AQSG 
ointments were administered topically, for evaluating the wound healing potential in 
excision wound model for fourteen days, in burn wound model for twenty one days, 
and in infected excision wound model for twenty one days. Povidone iodine was the 
standard for excision wound and silver sulfadiazine was used as the standard for both
burn and infected excision wound models.  Extracts treated groups showed higher in 
vitro antioxidant, anti microbial and cytoprotective activities. EASG exhibited similar 
wound healing activity that of the standard but with lesser magnitude.The result may 
be attributed to the phytoconstituents such as flavonoids and phenolics present in it 
which may be due to their individual or cumulative effect that enhanced wound 
healing and provided scientific evidence to the ethnomedicinal futures of Simarouba 
glauca. These findings could justify the inclusion of this plant in the management of 
wound healing.
Keywords: EASG, AQSG, Wound healing potential, Phytoconstituents. 
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1. INTRODUCTION
1.1 INTRODUCTION
This chapter presents; the background of the study, statement of the problem, 
definition of terms, purpose of the study, theoretical basis and organization of the 
remainder of the study.
1.1.1 Background of the Study 
Wound types are diverse, from acute to chronic and traumatic to surgical to 
disease-driven. But the range of products and under development to address them 
is even more varied. Current estimates indicate the worldwide nearly 6 million
people suffer from chronic wounds.[1] In developed countries, it is estimated that 1 
to 2% of the population will experience a chronic wound during their lifetime.[2]
Data shows a predictable global increase in surgical wounds, lacerations and 
traumatic wounds from 2012 to 2017, with a small projected increase in the 
prevalence of burns in this period. Other types of wound, such as amputations and 
carcinomas are also predicted to rise slightly. Even if it is small in number when 
compared to surgical wounds, the report shows that chronic wounds are the most 
challenging and high-cost wounds to manage, making them a target for 
development of technologies to manage them. It is also reported that, chronic 
wounds, such as pressure ulcers, venous ulcers and diabetic ulcers, are set to 
increase from a little over 40 million to over 60 million between 2012 and 2017.[3]
An estimated 265,000 deaths every year are caused by burns – the vast majority 
occur in low and middle-income countries. In 2004, nearly 11 million people 
worldwide were burned severely enough to require medical attention.[4]
Thirty five million cutaneous wounds requiring major intervention occur 
yearly in the U.S.A. alone. And it is been estimated that the total number of chronic 
wounds exceeds 2 million and possibly up to 5 million annually in the U.S.A. alone 
(1998). The social and financial levy of chronic wounds is very high. The common 
cause of acute wounds is thermal injury, and in each year 2.5 million people are 
suffering from burn injury, especially in USA. Other major type of acute cutaneous 
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wounds are caused by excision of extensive skin cancer, trauma and medical 
conditions such as deep microbial infections, vasculitis, scleroderma, pemphigus, toxic 
epidermal necrolysis to name a few. Classes of chronic wounds include arterial ulcers, 
venous ulcers, diabetic ulcers and pressure ulcers. It is estimated that the prevalence of 
leg ulcers alone is between 0.5%± 1.5% with an annual cost of nearly $1 billion.[5]
Chronic wounds represent a silent epidemic that affects a large fraction of the world 
population and poses major and gathering threat to the public health and economy of 
the United States.
In India, over 1,000,000 people are moderately or severely burnt every year.
The prevalence of wounds in the population studied (n=6917) was 15.03 per 1000. 
The prevalences of acute and chronic wounds were 10.55 and 4.48 per 1000 of the 
population respectively. The most common site for both acute and chronic wounds 
was the lower extremity. In contrast to Western studies, the most common etiology 
for a chronic lower extremity wound was an untreated acute traumatic wound. This in 
turn highlights the need to establish community-based wound-care teams in India.[6]
Wound infection is not a modern phenomenon. As early as 14-37AD there is 
documentary evidence that Cornelius Celsus (a Roman physician) described the four 
principal signs of inflammation and used 'antiseptic' solutions. Another Roman 
physician, Claudius Galen (130-200 AD) had such an influence on the management of 
wounds that he is still thought of by many today as the 'father of surgery'. It should 
also be remembered that he and some of his followers instigated the 'laudable pus' 
theory, which incorrectly considered the development of pus in a wound as a positive 
part of the healing process
The 2002 survey report by the Nosocomial Infection National Surveillance 
Service (NINSS), which covers the period between October 1997 and September 
2001, indicates that the incidence of hospital acquired infection (HAI) related to 
surgical wounds is as high as 10%. These infections complicate illness, cause anxiety, 
increase patient discomfort and can lead to death. The cost to the NHS is almost £1 
billion pounds per annum.[7]
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The incidence of burns in the US has dropped from 4.2 per 100,000 during the year 
1961 through 1964 to 1.5 per 100,000 during the period 1993 through 1996. 
Improvement in burn assessment and delivery care however needs further 
improvement to reduce medical transport and treatment costs.[8]
1.1.2 Statement of the Problem
Wounds are normally resolved in a few days, but chronic wounds represent a 
major burden because of social and economic factors. Thereby, the search for new 
agents is ongoing and natural products become a great target. Individual factors such 
as stress or diabetes can cause delay in the healing process or increase the risk of 
infection in the wound. Due to unawareness of the society this can lead to chronic 
diseases which may damage the other organs. Impaired wound healing results in
severe morbidity leading to long hospitalization of patients. States (US) population, 
which results in a significant economic burden estimated to be nearly 2–4% of the 
health budgets.[9]
Wound healing is the general repair response of the body immediately after 
the disruption of skin integrity. It is essentially composed of five interconnected and 
overlapping phases; haemostasis and inflammation, neovascularization, granulation, 
re-epithelization and remodeling. The treatment of wounds is sometimes challenging
especially in chronic wounds with a prevalence of 4.5 per 1000 population. Although
there has been vast development in pharmaceutical drug industry, wound healing 
drugs are not still satisfactory because of their low availability, high cost, and various 
detrimental side effects. Therefore, medicinal plant derived drugs is under great 
demand because of the common belief that they are safe, reliable, clinically effective, 
low cost, globally competitive and better tolerated by patients. Since ancient times, 
human beings have been using many plant resources based on empirical observations 
without any scientific knowledge for the treatment of wounds, cuts, and burns. 
Biologically active constituents of these plants such as tannins, triterpenoids, 
flavonoids and alkaloids have been found to affect one or more phases of wound 
healing process.
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1.1.3. Definition of Terms
1.1.3.1 Wound: A wound may be defined as a break in the epithelial integrity of the 
skin or may also be defined as a loss or breaking of cellular and anatomic or   
functional continuity of living tissue.[10]
1.1.3.2 Healing: Healing is a complex biological process including blood coagulation 
inflammation, fibroplasia, collagen deposition, and wound contraction.[11]
1.1.3.3 Epithelialization: The process of covering a denuded surface with epithelium 
or the process of assembling an epithelium from non-epithelial cells, such as in the 
process of mesenchymal to epithelial transition.[12]
1.1.3.4. Inflammation: A localized physical condition in which part of the body 
becomes reddened, swollen, hot, and often painful, especially as a reaction to injury 
or infection.[12]
1.1.3.5. Collagen: The main Structural protein in the extra cellular space in the 
various connective tissues.[14]
1.1.3.6. Angiogenesis: Physiological process through which new blood vessels from 
pre-existing vessels.[15]
1.1.3.7. Flavonoids: Flavonoids are ubiquitous in plants; almost all plant tissues are 
able to synthesize.  There are also a wide variety of types at least 2000 naturally 
occurring flavonoids. They can be classified into seven groups: flavones, flavonones, 
flavonols, flavononols, isoflavones, flavonols (catechins) and anthocyanidins. In 
general, the leaves, flowers, fruits, or the plant itself, contain flavonoid glycosides, 
while the woody tissues contain aglycones, and the seeds may contain both.[16]
1.1.3.8. Phytochemicals: Biochemicals derived from naturally-occurring plant 
sources, and may be beneficial for health or treatment of disease.[17]
1.1.3.9. Antioxidant: A substance that inhibits oxidation or reactions promoted by 
oxygen or any substance that prevents or reduces damage caused by reactive oxygen 
species (ROS) or reactive nitrogen species (RNS). ROS and RNS are highly reactive 
chemicals that attack other molecules and modify their chemical structure synthetic or 
natural substances added to products to prevent or delay their deterioration by action 
of oxygen in air. In biochemistry and medicine, antioxidants are enzymes or other 
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organic substances, such as vitamin E or beta-carotene that are capable of 
counteracting the damaging effects of oxidation in animal tissue.[18]
1.1.4 Theoretical Framework
Wound is a type of injury which happens relatively quickly where skin is cut, 
torn or punctured or where blunt force trauma causes a contusion . In a pathological 
way it refers to a sharp injury which leads to the damage of dermis of the skin. Wound 
can be classified based on the contamination like clean wound contaminated wound, 
Infected wound and Colonized wound: or can be classified as acute and chronic 
wound based on the severity, or it may be open or closed. The cutaneous response to 
injury and stress comprises a temporary change in the balance between epidermal 
proliferation and differentiation as well as an activation of the immune system. 
Soluble factors play an important role in the regulation of these complex processes by 
coordinating the intercellular communication between keratinocytes, fibroblasts, and 
inflammatory cells. The process of wound healing may be presented as a series of 
separate events. In actuality, the entire process is much more complicated, as cellular 
events that lead to scar formation overlap. Many aspects of wound healing have yet to 
be elucidated.[19] Cutaneous wound healing is a complicated, multistep process with 
numerous mediators that act in a network of activation and inhibition processes.
Current understanding of the complex process of wound repair is based on decades of 
study. Now that major wound processes are more fully understood, therapeutic 
strategies can be developed to manipulate wound repair.
Animal models always provide crucial insights into the mechanisms and 
pathophysiology of cutaneous wound repair. Various aspects of the healing process 
can be characterized and quantified in a controlled and reproducible environment. 
Various types of normal and pathological injury paradigms can be applied in both 
small and large animal species. To mimic clinical problems, rates of repair can be 
compromised by surgical impairment of blood supply or metabolic manipulations 
such as the diabetic state. Even though animal wound repair is an imperfect reflection 
of human wound healing and its clinical challenges, these models continue to be 
crucial tools for the development of new strategies and approaches to rational wound 
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therapy.[20] The number of studies that use animal models for wound healing has been 
increasing recently. However this is not surprising considering the number of new 
products that are introduced each year. There are numerous types of in-vivo models 
available, and each has unique benefits and disadvantages.
Rodent and small mammal models for wound healing have emerged as the 
model of choice for many researchers all over the world. This type of animal study is 
valuable to wound research for multiple reasons. Small animals are inexpensive, 
easily obtainable, and require less space, food, and water. Moreover, these animals
often have multiple offspring, which develop quickly allowing experiments to 
proceed through multiple generations. Small animals generally have accelerated 
modes of healing when compared to humans, thus experiment duration lasts for days, 
whereas it takes weeks or months in human experiments. Likewise some small 
animals can easily be altered genetically and provide a wound model capable of 
resembling defective human conditions such as diabetes, immunological deficiencies, 
and obesity. Another advantage of these models is their ability to serve in 
experiments where death is an endpoint, as in some cases of bacterial or viral 
infection.[21]
Animal models have been available for decades, yet historically in the wound 
healing field translation of candidates identified in animal models to human therapies 
have been problematic. Indeed, most will agree that while invaluable for uncovering 
important pathways and processes, current animal models are not well suited to 
preclinical evaluation of therapeutic candidates. With the caveat of known intrinsic 
differences to human repair, the mouse model system provides an abundant, 
manipulatable, accurate tool for wound repair study and is likely to remain the model 
of choice to mechanistically probe the process for the foreseeable future.[22] The 
various animal models that are used to interpret the wound healing potential are acute 
Wound Models, Impaired Healing Models, Immunologic, Chronic Wound Models. 
The experimental models used in this study are:
ß Excision wound model
ß Burn wound model
ß Organism induced wound model
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Excision wound model: Excision wound involves the removal of great amount of 
tissues and is useful in evaluating the wound closure, re-epithelialization grade, 
inflammation, wound maturation, neo-angiogenesis and remodeling process. This 
model is useful in determining the biochemical and histological parameters. It include 
tape stripping, blisters, split-thickness, full thickness, splinting.
Burn wound model: Chemical or radiation burns the skin or other tissues produce a 
remarkably different healing response due to their effect on the viability of cells and 
tissues. The depth of the burn may be designated as first, second, or third degree. 
Thermal burns in particular create an extensive zone of frank necrosis that includes 
dead cells and denatured or even charred connective tissue. This model is used to 
study the pathogenesis of skin damage and allowing determination of three basic 
phases which occur during wound healing
Infecetd excision wound model: Creating wound on the back of mice followed by 
the inoculation of micro-organism to the wound area. In this model bacterial 
colonization-wound biofilm helps to explain many of the complex challenges that are 
clinically observed. A stabilized mature biofilm will induce an effect on the wound 
that will delay healing and induce a local infection.[23]
These models replicates the events observed in patients with acute and chronic 
wound, and therefore serve as a useful and relevant model for studying the healing 
potential.
1.1.5 Purpose of the Study
Traditional medicine practitioners have described the therapeutic efficacies of 
many traditional and indigenous plants against diseases.  A large number of plants are 
used by folklore traditions in India for treatment of cuts, wounds and burns. Various 
research data revealed that plants may worked in healing and regeneration of the 
tissue by multiple mechanisms. There are several reports stating that the extracts of 
several plants, used for wound healing properties. Natural products that are safe, and 
possess physiological properties are excellent sources of new therapeutics for the 
treatment of conditions like mechanical damage of the skin. Some researchers
therefore have shifted their focus to the potential wound healing properties of plants.
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Wounds are normally resolved in a few days, but chronic wounds represent a major 
burden because of economic and social factors. Thereby, the search for new agents is 
ongoing and natural products become a great target. Various literatures and studies 
show that the active principles triterpinoids, Quassanoids and flavonoids are having a 
crucial role in healing acute and chronic wounds. Simarouba glauca is rich in these 
types of triterpinoids, Quassanoids and Flavonoids. The purpose of this study is to 
investigate and evaluate wound healing activity on various wound model by using 
ethylacetate and aqueous extracts of Simarouba glauca.[24]
1.1.6 Hypothesis
I hypothesizethat the presence of active constituents like triterpenoids,
quassinoids and flavonoids in this plant Simarouba glauca after isolation and 
extraction is having protective effect in healing wounds. To test whether the plant 
possess the same activity, different wound models are selected. The result of these 
studies will have a translational value to wound healing effect.
The following specific aims will be pursued to achieve my objectives
1.1.7 Specific Aims
1. To determine the in-vitro anti-oxidant capacity of leaves of Simarouba glauca
2. To determine the In-vitro cytotoxic effect of leaves of Simarouba glauca
3. To determine the in-vitro anti-microbial potential of leaves of Simarouba 
glauca on different micro-organisms.
4. To employ the leaves of Simarouba glauca in short term different wound 
models to  determine wound healing effect by
ß Excision wound model
ß Burn wound model
ß Organism induced wound model
Introduction
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1.1.8 Organization of the Remainder of the Study
The remainder of the study will consist of the following .Chapter II will 
review the literature on plant of Simarouba glauca. Chapter III will detail the research 
design and methodology of this study. Chapter IV will present the data collected. 
Chapter V will present the findings, conclusions and recommendations of this study. 
The references list works cited in the study
Plan of work
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2. PLAN OF WORK
1. Review of Literatures
2. Selection, Collection And Authentication of Plant Material
3. Extraction  of plant materials with petroleum ether, ethyl acetate and 
water
4. Preliminary phytochemical analysis & chromatographic Screening
5. Quantification of total phenol and flavanoid content
6. In vitro antioxidant study
∑ DPPH radical scavenging assay
∑ ABTS radical cation assay
7. Invitro cytotoxicity study by MTT assay
8. Invitro anti-microbial studies
9. Pharmacological study
¸ Screening of wound healing activity using various models
∑ Excision wound model
∑ Burn wound model
∑ Infected excision wound model
¸ Invivo activity
∑ Evaluation of parameters
a. Percentage wound contraction
b. Epithelialization time
c. Tissue breaking strength
d. Total protein
e. Hydroxy proline
f. Hexosamine
g. Uronic acid
Plan of work
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∑ In-vivoAntioxidants assays
ÿ Enzymatic antioxidants(SOD,CAT,)
ÿ Non-enzymatic antioxidant(GSH)
ÿ Estimation of Lipid peroxidation(LPO)
10. Histopathological study
11. Statistical analysis
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3. REVIEW OF LITERATURE
3.1. WOUND
A wound may be defined as a rupture or  break in the epithelial  integrity of 
the skin or it can  be defined as a loss or breaking of cellular, anatomic and  functional 
continuity of living tissue as a result of  trauma or violence followed by damage or 
disruption of underlying normal tissue. 
Or it can also be defined as a type of injury which happens relatively quickly 
where skin is cut, torn or punctured or where blunt force trauma causes a contusion . 
In a pathological way it refers to a sharp injury which leads to the damage of dermis 
of the skin.
Every year, millions of people experience burns, suffer from chronic wounds, 
or have acute wounds that become complicated by infection, dehiscence or 
problematic scarring. Now a day it is considered as the major problem in the field of 
clinical practice[26]
3.2 CLASSIFICATION[26]
Based on the level of contamination
 Clean wound
 Contaminated wound
 Infected wound
 Colonized wound
Clean wound : These type of wounds are made under sterile conditions where they 
are devoid of micro-organisms and they likely to heal without any complications.
Contaminated wound: These kind of wounds shows the presence of pathogenic 
micro-organisms and foreign bodies as a result of accidental injury.
Infected wound: infected wound also shows the presence of pathogens, clinical signs 
of infection where it will be yellow in color, filled with pus along with pain and 
redness.
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Colonized wound: Chronic wound where the healing is very difficult and also filled 
with pathogens.
Based on the duration of healing it can be classified as:
 Acute wounds 
 Chronic wounds
3.2.1 ACUTE WOUNDS[27]
Acute wounds heal without any complications in the predicted amount of time.
Causes of Acute Wounds
 Sharp pointed objects like nail, jagging or poking into the body
 Rough surfaces rubbing and scraping against the skin
 Sharp blades or edges like knife, cutting the skin cleanly
 Hard blows by objects, tearing the tissue roughly by sheer force
Types of acute wounds
1. Surgical wounds:  These wounds are made purposefully, it may be closed or 
left open for healing. Surgical wound will be always clean, but sometimes it 
may be contaminated due to infection of micro-organism.
2. Traumatic wounds: Caused by force or impact of some nature. Eg: incision, 
abrasion.
Signs and symptoms:
The major signs and symptoms include pain, bleeding at the site of injury. The skin 
that surrounds the wound may be open and appeared to be torn. Infected wound may 
have foul smell, pus, and the area surrounds the infected wound may be red, tender 
and swollen.
3.2.2 CHRONIC WOUNDS[28]
These kinds of wound usually take longer time for healing and lead to complications.
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Causes of chronic wounds:
Failure or delay in wound healing may due to lack of one or more of the main 
factors of healing including good supply of oxygen, blood, nutrients and clean and 
infection free environment.
Types:
1. Infectious wounds: If the infection is not treated properly, it will not heal in 
the expected time.
2. Ischemic wounds: The wound area will be ischemic that there will be 
insufficient blood supply. So the supply of oxygen and nutrients will be 
limited leading to delay in wound healing.
3. Radiation wound: Excessive exposure to ionizing or radiating materials
weakens the immune system, causes damage to the exposed tissues and delay 
the healing time of all wounds.
4. Surgical wounds: This type of wounds can progress in to chronic wounds if 
the blood supply to the surgery area is accidentally damaged or the  wound 
care is inadequate. It may eventually leads to delay in wound healing.
5. Ulcers (the most common type of chronic wounds):- Arterial ulcers, Venous 
ulcers, Diabetic ulcers, Pressure ulcer
Signs and Symptoms
The signs and symptoms may differ based on the type of chronic wounds.
Infectious wounds: these are typically associated with pus drainage, bad odor, debris 
(yellowish to greenish) or dead tissue, and ongoing symptoms of inflammation like 
fever, pain, redness, hotness and swelling.
Ischemic wounds: Typically the affected area will be pale and cold. Hair growth will 
be diminished and there might be a weak pulse sensation in the area.
Radiation poisoning wounds: Usually associated with redness, itching, blistering, 
inflammation and also other unspecified symptoms that include vomiting, nausea, 
fever  and abdominal pain.
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Surgical wounds: Generally occur at the site of surgical incision, but instead of a 
clean appearance, the tissue around the incision appears red, hot, and swollen, which 
can be inflamed or infected.
Ulcers: It may vary based on the type of ulcers, These ulcers are superficial, shallow, 
and irregularly shaped with pain and edema Diabetic ulcers: These can be either of 
neuropathic (secondary to nerve damage) origin, where the lack of sweat makes the 
skin dry and easy to crack and scale, forming callus (accumulation of dead skin 
layers). Pressure Ulcers includes itching, blistering, hotness, swelling and 
discoloration of the area.
3.2.3 OPEN WOUNDS[29]
In open wounds the underlying tissues will be exposed or the organs are open 
to the outside environment as seen in the case of penetrating wounds.
Causes, Types and Symptoms
1.Abrasion: Shallow irregular wounds appear on the upper layers of skin usually with 
minor to no bleeding. Abrasion occurs due to skin brushing with a smooth surface at a 
high speed or with rough surface. These kinds of wound have mild pain that subsides 
shortly after the initial injury.
2.Lacerations: Tear like wounds usually deeper than abrasions with irregularly torn 
edges and cause more pain and bleeding. Lacerations commonly caused by contact 
with objects like hard blows, accidents or collusions or trauma.
3.Incisions: incision type wound usually results from surgical procedure or skin cut 
with sharp objects such as; scalpels, knives and scissors. These are linear in shape 
with smooth, sharp edges. Depending on the depth and site of the wound it can be life 
threatening if it involves vital organs, nerves or major blood vessels.
4.Punctures: Punctures are small rounded wounds results from objects with very thin 
pointed tips like nails, needles, or other tapered objects and with teeth in cases of 
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animal or human bites. The wound depth, size, pain and bleeding are directly related 
to the force and size of causative object.  
5. Penetrating: these types of wounds are caused by force or any objects that breaks 
through the skin to the underlying tissues or organs. And have variable shapes, size 
and presentations; based on the cause. These can be life threatening, causing severe 
damage especially to nerves, blood vessels and even to vital organs.
3.2.3.1 COMPLICATIONS[30]
1. Infection: Most open wounds are caused by contaminated objects that carry 
different variety of micro-organisms. These kinds of wound present a foul odor, 
pus, fever and pain.
2. Inflammation: Results from the body’s immune response to foreign  materials 
that caused a wound. This will make the wound area red, swollen, hot and even 
painful. 
3. Scarring: These kinds of wounds will leave a scar after healing, sometimes lead 
to the deformity of the affected area; particularly with gunshot, penetrating or 
deep laceration wounds.
4. Loss of function: Depending on the severity of the wound and the damage to the 
affected area the loss of function can be temporary or permanent.
3.2.4 CLOSED WOUNDS[31]
Closed wound usually refers to internal injury where there is no break in the 
continuity of the skin and underlying tissues. 
Causes, Types and Symptoms
Closed wounds are generally caused by forceful impact of a blunt object to the skin, 
where the skin is not broken but the tissues underneath it may be extensively crushed 
or the damage can reach down to the underlying tissue, muscle, internal organs and 
bones.
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1. Contusions: These are mostly known as the bruises accompanied by bleeding 
for a few hours followed by swelling within 24-48 hours or immediately after 
the injury. Swelling occurs as a result of collection of blood beneath the skin 
of damaged tissues. Contusions are painful bruise with reddish to bluish 
discoloration that spread over the injured area.
2. Hematomas: Hematomas are the type of injuries that usually damages the 
capillaries and small blood vessels leading to pooling of blood in a limited 
area. These are normally painful, rubbery spongy lump like lesions. 
Depending on the severity and type of trauma it can be small or large, under 
the skin or deep inside.
3. Crush injuries: Crush injuries are most commonly caused by an external high 
pressure force that squeezes part of the body between two surfaces. Depending 
on the size, power, duration and site of the trauma the degree of pain and 
injury can range from a minor bruise to a complete destruction of the damaged 
area.
3.2.4.1 COMPLICATIONS
1. Severe bleeding, nerve damage, large bruises, and internal organ damage.
2. Compartment syndrome: increased pressure and swelling in the fascia that 
surrounds the nerves, muscles and blood vessels in that area. The blood 
supply to the affected limbs will be blocked due to increased pressure, 
causing damage to nerves and muscles. Permanent damage leads to loss of 
function and may necessitate amputation. 
3.3 HEALING[32]
    Tissue injury may result in tissue destruction and cell death. On the other hand it is 
the response of the body specifically to injury as an attempt to restore normal 
structure and function. Healing involves two distinct processes: At times these two 
processes take place simultaneously.
 Regeneration- where the healing takes place by proliferation of parenchymal 
cells and results in the complete restoration of the original tissues.
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 Repair- Here instead of the parenchymal cells, proliferation of the connective 
tissue elements will takes place resulting in fibrosis and scarring.
Table 1: Phases of healing process
Phase                                                       Cellular and bio-physiologic events
Hemostasis                                               1. Vascular constriction
                                                                  2. Platelet aggregation, degranulation, and                               
                                                                      fibrin formation(thrombus)
Inflammation                                             1. Neutrophil infiltration
                                                                   2. Monocyte infiltration and differentiation
                                                                       to  macrophage                                                                                                                                      
                                                                   3. Lymphocyte infiltration
Proliferation                                              1. re-epithelialization
                                                                  2. angiogenesis
                                                                  3. collagen synthesis
                                                                   4. ECM formation
Remodeling                                              1. collagen remodeling
                                                                   2. vascular maturation and regression
3.3.1 REGENERATION
In order to maintain the proper structure and function of the tissues, the cells are 
under constant regulatory control of their cell cycle.  It includes growth factors such 
as Fibroblast growth factor, epidermal growth factor, endothelial growth factor, 
platelet-derived growth factor, transforming growth factor-β. 
Cell cycle: It is the phase between two successive cell divisions and is divided into 4 
unequal phases.
M PHASE: Phase of mitosis
G1 Phase: Gap 1 phase- After mitosis daughter cells enters G1 phase.
S Phase: Synthesis Phase- Synthesis of nuclear DNA takes place at this phase
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G2 Phase: Gap 2 Phase- The cells enters G2 phase after the completion of the nuclear 
DNA.
G0 Phase: Gap 0 phase- this is the resting or inactive phase of the cell after an M 
phase.
Depending on the dividing capacity, the cells of the body can be classified into 3
1. Labile cells:  Under normal physiologic conditions these types of cells 
multiply throughout the life. Eg: Surface epithelial cells of epidermis, 
respiratory tract, alimentary tract, vagina cervix, urinary tract, uterine 
endometrium, cells of lymph nodes, bone marrow and spleen. 
2. Stable cells: The ability of the cells to proliferate will decrease or lose after 
reaching adolescence, but retains the capacity to divide in response to stimuli 
throughout their life. Eg: Parenchymal cells of various organs like liver, 
kidneys, pancreas, thyroid and adrenal; mesenchymal cells like fibroblasts, 
smooth muscle cells, vascular endothelium, cartilage and bone cells.
3. Permanent cells: These types of cells loss their ability at the time of birth. 
These include: cardiac and skeletal muscle cells, neurons.
3.3.2 REPAIR[33]
     Repair is defined as the replacement of injured tissue by fibrous tissue.
Repair involves two processes: 
1. Granulation tissue formation
2. Wound contraction
Granulation Tissue Formation
           The name granulation tissue derived from the slight granular and pink 
appearance of the tissue.  The granulation tissue consist of granules, histologically 
corresponds to proliferation of new small blood vessels which are slightly lifted from 
the surface by thin covering of fibroblasts and young collagen.
The phases of granulation tissue formation includes
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 Phase of inflammation:  The blood clots at the site of injury after
trauma, followed by acute inflammatory response along with exudation 
of plasma, some monocytes and neutrophils within 24 hours.
 Phase of clearance: Here all the necrotic tissues, red blood cells and 
debris will be cleared off by the combination of liberated proteolytic 
enzymes from neutrophils, autolytic enzymes from dead tissues, and 
phagocytic activity of macrophages.
 Phase of ingrowths of granulation tissue: it includes two main steps or 
processes.
Angiogenesis- Formation of new blood vessels at the injured site.
Fibrogenesis- Formation or development of fibroblast from the 
  fibrocytes and mitotic division of fibroblast. 
Figure 1. Phases of wound healing, major types of cells involved in each phase, 
and selected specific event
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3.4 CONTRACTION OF WOUNDS[34]
     The wound starts to contract after 2-3 days and the process will be completed 
in 14 days. During this time period the wound size is reduced by approximately 80% 
of its original size. This contraction of wound results in rapid healing since lesser 
surface area of the injured tissue has to be replaced.
The proposed mechanism of wound contraction can be explained by using various 
factors, These include: 
1. Dehydration:  Removal of fluid from drying wound leads to dehydration. This 
was the first suggested mechanism but without being substantiated.
2. Contraction of collagen: This was thought to be responsible for wound 
contraction but contraction proceeds even when the availability of collagen 
content in the granulation tissue is very less.
3. Discovery of myofibroblasts: The presence of myofibroblast in the active 
granulation tissue put to an end to the controversies surrounding the wound 
contraction and its mechanisms. The migration of these cells to the wound 
area and their active contraction is said to be responsible for the reduction of 
the wound area. The evidences that support this concept are morphological 
and functional characteristics of this modified fibroblasts or myofibroblasts, 
like
a. Fibrils present in these cells resemble those seen in smooth muscle 
cells
b. The actin-myosin found in these cells are similar to that found in the 
non-striated muscle cells.
c. The nuclear membrane shows infoldings like in smoothmuscle cells
d. They differ from the ordinary fibroblast cells as these cell have 
basement membrane and desmosomes.
e. The drug responseof granulation tissue and smooth muscle are 
similar.
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3.5 WOUND HEALING
Healing may be defined as a complex biological process including blood 
coagulation inflammation, fibroplasia, collagen deposition, and wound contraction.
3.5.1 CUTANEOUS WOUND HEALING[35]
          Cutaneous wound healing is a typical example of combination of regeneration 
and repair. Although most of the skin lesions heal efficiently, the end product may not 
be functionally perfect. Epidermal appendages do not regenerate, and leads to the 
formation connective tissue scar in place of the mechanically efficient meshwork of 
collagen in the unwounded dermis. In case of superficial wounds the epithelium will 
be reconstituted and there may be little scar formation. Cutaneous wound healing is 
divided in to three phases:
1. Inflammation (early and late)
2. Granulation tissue formation
3. Re-epithelialization
4. Wound contraction
5. ECM deposition
6. Remodeling.
Wound healing is a fibroproliferative response which is mediated through growth 
factorsand cytokines.
Table 2: Growth Factors and Cytokines Affecting various Steps in Wound 
Healing
Monocyte chemotaxis                    PDGF, FGF, TGF-β
Fibroblast formation                     PDGF, FGF, TGF-β, TNF, IL-1
Fibroblast Proliferation                 PDGF, FGF, TGF-β
Angiogenesis                                  VEGF, Ang,FGF
Collagen synthesis                         TGF- β, PDGF
Collagenase secretion                    PDGF, FGF, EGF, TNF, TNF- β
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3.5.1.1 Healing by first intention OR Primary union (Wounds with opposed 
edges) 
       The least complicated examples of a repair is the healing of a wound with the 
following characteristics like
i. Clean and uninfected
ii. Surgically incised,
iii. without much loss of cells and tissues and
iv. the edges are approximated by surgical sutures
Healing of these kind of wounds are referred to as Primary union or healing by 
first intension.
The incision or the surgical incision causes death of a limited number   
epithelial cells and connective tissue cells, also it disrupts the continuity of the 
epithelial basement membrane. The surgical wound results in narrow incisional space 
which will be immediately filled by clotted blood containing blood cells and fibrin, 
And the clotted blood undergo dehydration and forms a well-known scab that covers 
the injured area(wound).
The primary union follows a series of sequential events:
i. Initial haemorrhage: It will start immediately after the injury, where the 
space between the approximated surface of the incised wound is filled with 
blood, which  then clots and seals the wound from infection and 
dehydration.
ii. Acute inflammatory response: This stage occurs within 24 hours with the 
appearance of neutrophils which gradually moves towards the fibrin clot. 
iii. Epithelial changes: The next 24 hour will witness for the movement of 
spurs of the epithelial cells from the wound edges( with little cell 
proliferation) along the cut margins of the dermis, where they deposit the 
basement membrane components as they move. These will fuse in the 
midline underneath the surface scab, producing a thin continuous epithelial 
layer that closes the wound. A well approximated wound will be roofed by 
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a layer of epithelium in 48 hours. The underlying viable dermis will be 
separated from the overlying necrotic material and clot by these migrated 
cells, leading to the formation of scab, which is cast off.
By third day these polymorphs will be largely replaced by the macrophages, 
and the granulation tissue invades the incision space progressively, and the 
collagen fibers will be present at the incision margins.
iv. Organisation: By the third day fibroblast invade the wound area and by the 
fifth day collagen fibrils starts forming, which dominates till healing is 
completed. The incisional space will be filled with the granulation tissue 
and neovascularization is maximal. The abundant collagen fibrils begin to 
bridge the incision. The epidermis will recover its normal thickness, and 
differentiation of the surface cells leads to the formation of a mature 
epidermal architecture with surface keratinization. 
During the second week there will be continued proliferation of fibroblasts 
and accumulation of collagen. The edema, Leukocyte infiltrate and 
increased vascularity have mostly disappeared by this time. In four weeks, 
the scar tissue with scanty cellular and vascular elements, a few 
inflammatory cells and epithelialized surface is formed.
v. Suture tracks: Each suture track can be considered as a separate wound and 
comprehence the same phenomena as in the healing by primary union. And 
include the events like haemorrhage, inflammatory response, epithelial cell 
proliferation from both margins along the suture track, formation of young 
collagen and fibroblastic proliferation. The sutures can be removed on the 
seventh day and by that time most of th epithelialized suture tr acks will be 
avulsed and the epithelial tissue will be absorbrd. In some cases the suture 
track gets infected and it leads to stich abscess, or the epithelial cells may 
remain in the track owing to implantation or epidermal cysts.
In all the way the scar formed in the sutured wound will be neat because of 
the close apposition of the margins of the wound; on the other hand use of 
adhesive tapes avoids removal of stitches and its complications.  
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Figure 2: Primary union of skin wounds: A, The incised wound as well as suture 
track on either side are filled with blood clot and there is inflammatory response from 
the margins. B, Spurs of epidermal cells migrate along the incised margin on either 
side as well as around the suture track. Formation of granulation tissue also begins 
from below. C, Removal of suture at around 7th day results in scar tissue at the sites 
of incision and suture track.
3.5.1.2 Healing by second intention (secondary union) or wound with separated 
edges:
It is defined as the healing of a wound with the following characteristics like
1. Open with a large tissue defect and may be infected
2. Having extensive loss of cells and tissues and
3. The wound is not approximated by surgical sutures but left open
When there is extensive loss of cells and tissue, as in surface wounds which 
create large defects and in such cases the repair and healing process will be 
complicated. Regeneration of the epithelial cells fails to bring out the original 
architecture, and as a result there will be massive growth of the granulation tissue 
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from the margin to complete the process of repair. This particular type of healing is 
referred to as healing by second intention.
     The healing events in both union are same, except in having large tissue defect 
which has not to be bridged. For this reason healing takes place from the margins 
inwards and from the base upwards. Hence when compared with primary union the 
healing by secondary union is a slow process leads to the formation of large, 
sometimes ugly scar.
The sequential events are 
1. Initial haemorrhage: The wound area is filled with blood fibrin clot.
2. Inflammatory phase: Starts with initial acute inflammatory response followed by 
the appearance of macrophages.
3. Epithelial changes: The epidermal cells proliferate along the margins of the 
wound and migrate in to the wound as epithelial spurs and these spurs completely 
reepithelialize the gap. On the other hand the proliferating epithelial cells do not 
cover the surface fully till the granulation tissue from base has started filling the 
wound space. Thus the pre existing viable connective tissue will be separated 
from the necrotic material and clot on the wound surface, forming scab which is 
cast off. Eventually the regenerated epidermis becomes stratified and keratinized. 
4. The main event in secondary healing is the granulation tissue formation, which is 
formed by proliferation of fibroblasts and angiogenesis from the adjoining viable 
elements. The newly formed such type of tissues will be deep red in colour, 
granular and very fragile. Gradually the matured scar became whilte and pale in 
color due to decreased vascularity and increased collagen deposition. The 
specialized structures of the skin like sweat glands and hair follicle are not 
replaced due to the failure of the structures to regenerate.
5. Wound contraction: The important feature of secondary healing is the wound 
contraction. The myofibroblasts of the granulation tissue aids in faster healing 
and it contracts the wound to one third to one fourth of the original size.
6. Presence of infection: infection or bacterial contamination delays the healing 
process as these organism release bacterial toxins that provoke necrosis, 
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thrombosis and suppuration. This bacterial contamination can be prevented by the 
surgical removal of the dead and necrosed tissue.
               
Figure 3: Secondary union of skin wounds. A, The open wound is filled with blood 
clot and there is inflammatory response at the junction of viable tissue. B, Epithelial 
spurs from the margins of wound meet in the middle to cover the gap and separate 
the underlying viable tissue from necrotic tissue at the surface forming scab. C, After 
contraction of the wound, a scar smaller than the original wound is left.
3.6 LOCAL AND SYSTEMIC FACTORS THAT INFLUENCE WOUND 
HEALING.[36]
   There are number of known and unknown factors that modify the healing 
process, which frequently impairs the adequacy and quality of both inflammation and 
repair. And these influencing factors are 
1. Local factors
2. Systemic factors
Local factors include:
3. Infection- leads to persistent injury and inflammation
4. Mechanical factors- like early motion of wounds delay the healing by 
compressing blood vessels and separating the edged of the wound.
5. Foreign bodies- fragments of steel, glass, or even bone and sutures delays the 
healing.
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6. Size, location and type of wound also influence the healing rate. Wounds present 
in the highly vacsularized area like face heals faster than those of the poorly 
vascularized area such as foot
Table 3: Factors that retard healing
Systemic factors include:
A. Nutrition has profound effect on wound healing. Protein and vitamin deficiency 
leads to delay in wound healing especially in cases of Vitamin c deficiency.
B. Metabolic status- Metabolic status highly influences the repair process 
particularly in Diabetes mellitus. Delayed wound healing is one of the major 
complications faced by the diabetic patients, where it occur as a consequence of 
the microangiopathy. 
                                  Factors that retard wound healing
Local factors
Blood supply                                            Mechanical stress
Denervation                                              Necrotic tissue
Local infection                                           Protection(dressings)
Foreign body                                             Surgical techniques
Hematoma                                                Type of tissue
Systemic factors
Age                                                           Anemia
Malnutrition                                            Obesity
Drugs(steroids, cytotoxic mediations,     Systemic infection
Intensive antibiotic therapy)                    Trauma, hypovolemia and hypoxia
Genetic disorders(osteogenesis,              Temperature 
imperfect,  Ehlers-Danlos syndromes,    Uremia
Marfan syndrome)                                   Vitamin deficiency ( vitamin C)   
Hormones                                                Trace metal deficiency (zinc, copper)
Diabetes                                                   Malignant disease                                                              
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C. Circulatory status: Inadequate blood supply caused by venous abnormalities like 
varicose veins or arteriosclerosis retards venous drainage and leads to impaired 
or delayed wound healing. 
D. Hormones: Hormones like glucocorticoids have significant anti-inflammatory 
effect, and that influences various factors of inflammation. And these hormones 
having profound role in inhibiting collagen synthesis.
3.7 COMPLICATIONS OF WOUND HEALING [37][38]
The abnormalities in any of the basic components of healing process eventually 
lead to complications. These aberrations are grouped in to three main categories.
1. Deficient scar formation
2. Excessive formation of the repair components
3. Formation of contractures.
During the process of healing the following, the following complications may occur:
1. Infection: Infection of wound delays the healing
2. Implantation cyst : The persistence of epithelial cells in the wound after the 
healing process is known as implantation or epidermal cyst formation
3. Pigmentation: Healed wound sometimes have rust like color. This coloration is 
due to the haemosiderin staining. And sometimes these colored particulate 
materials may persist and impart specific color to the healed wound area.
4. Deficient scar formation:  At times the formation of the granulation tissue will be 
inadequate and ends in deficient scar formation.
5. Incisional hernia: Formation of weak scar especially after laparotomy, ends in the 
formation of incisional hernia or wound dehiscence.
6. Excessive contraction: Excessive contraction of wound may result in formation of 
cicatrisation or contractures. Eg: Plantar contracture, Palmar contracture, and 
Peyronie’s disease.
7. Hypertrophied scars and keloid formation: Sometimes there will be exaggerated 
scar formation and which will be painful. Excessive collagen formation result in 
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keloid (claw like) formation and it is more common in blacks. Hypertrophied 
wounds are confined to the borders of the initial wound whereas keloids consist 
of tumor like projection of connective tissue.
8. Neoplasia: The scars may act as the site for the development of the carcinoma 
like the squamous cell carcinoma in Marjolin’s ulcer that is the scar following 
burns on the skin.
3.8 WOUND INFECTION[39]
The development of a wound infection depends on the complex interplay of 
many factors. If the integrity and protective function of the skin is breached, large 
quantities of different cell types will enter the wound and initiate an inflammatory 
response. This may be characterised by the classic signs of redness, pain, swelling, 
raised temperature and fever. This process ultimately aims to restore homeostasis
   3.9 Potential wound pathogens
The most of the micro-organisms are less than 0.1mm in diameter and can 
therefore only be seen under a microscope. 
3.9.1 Bacteria
These are relatively simple cells that can be further categorised according to 
differences in their shape and cell wall. Cocci (spherical shaped cells), bacilli (rods) 
and sprirochaetes (spirals) can be arranged singly; however cocci and bacilli can also 
be found in pairs, chains and irregular clusters. They can be visualised using a 
bacteriological staining process called Gram staining; after Gram staining, Gram-
positive bacteria are purple and Gram-negative bacteria are red. Species that fail to 
stain with the Gram reaction, such as Clostridia, require specialised stains. 
3.9.2 Fungi
These are composed of larger more complex cells than bacteria. They are 
either single-celled yeasts or multi-cellular organisms with a nuclei contained within a 
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cell membrane. Fungi can be responsible for superficial infections of the skin, nails 
and hair and, although they have been isolated from wounds, they are rarely 
pathogenic in this setting.
3.9.3 Protozoa
These are single celled organisms within a fragile membrane and without a 
cell wall. They are most significantly associated with infected skin ulcers.
3.9.4 Viruses
These are composed of genetic material (nucleic acid) enclosed within a 
protein coat or a membranous envelope. Although viruses do not generally cause 
wound infections, bacteria can infect skin lesions formed during the course of certain 
viral diseases.
It is important to remember that different micro-organisms can exist in 
polymicrobial communities and this is often the case within the margins of a wound
3.9 BURN WOUND[40]
Burns or burn wounds are so much different from other wounds that a separate 
medical superspeciality has been designated to manage them. Even though extensive 
burns primarily involve a single organ; however, almost all systems of the body are 
affected in this disease making it a generalized disorder. Unlike any other traumatic 
wound, involvement of intensivist and physician is more in burns.
3.9.1  ETIOLOGY
The cause of burn injury may be thermal or non thermal. Thermal include 
thermal contact, flame, or scald. Non thermal include such as chemical, electrical or 
radioactive. Chemical injuries are a result of contact with substance that are toxic to 
skin or lining of respiratory and alimentary tract loke acid,alkali etc. Electric burns 
results from conduction of electric current through body. 
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3.10 Treatment
Once a diagnosis of wound has been confirmed and antibiotic sensitivities 
identified, appropriate management regimens should be considered, with a high 
priority given to reducing the risk of cross infection. It is important to treat the patient 
as a whole and not the infection alone, so management strategies must be based on 
data derived from a holistic assessment of the needs of the individual. The main 
treatment objective will be to reduce rather than eradicate the bacterial burden within 
the wound margins. In addition to antibiotic therapy, there are two main generic 
groups of wound management products that have the potential to reduce the bacterial 
burden in the wound, these are compounds containing silver or iodine.
3.10.1 Antibiotic therapy
Antibiotics are chemical substances produced by a micro-organism that have 
the capacity, in dilute solutions, to selectively inhibit the growth of or to kill other 
micro-organisms. Whereas it is now generally accepted that systemic antibiotics are 
essential for the management of clinically infected wounds, the choice of antibiotic to 
be used is not always apparent. Only after a comprehensive assessment process 
including consideration of patient characteristics, the results of microbiological 
investigations and the identification of both the nature and location of the wound, can 
the most appropriate antibiotic be identified.
The routine use of topical antibiotics is not justified for colonised or infected 
wounds. In addition, a recent systematic review of antimicrobial agents has concluded 
that systemic or topical antimicrobials are not generally indicated for the management 
of chronic wound infections. However, there may be some value in the prophylactic 
use of topical antimicrobials for the initial management of acute cellulitus, whilst 
awaiting clarification of antibiotic sensitivity and the establishment of a therapeutic 
regimen.
Resistance to antibiotics has become a serious problem in recent years 
particularly with the rise of epidemic strains of MRSA. The overuse of broad-
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spectrum antibiotics will only serve to exacerbate the situation. It could therefore be 
argued that all antibiotic use should be based on known sensitivities.
3.10.2 Iodine
Iodine is an element that has antiseptic properties. It is active against a number 
of pathogens. In the past its use has been limited by the fact that elemental iodine can 
be absorbed systemically, is almost insoluble and can be an irritant to the skin.
In wound management iodine is used in two forms:
 Cadexomer iodine - a polysaccharide starch lattice containing 0.9% elemental 
iodine that is released on exposure to wound exudate.
 PVP-1 (Povidone iodine) - an iodophor composed of elemental iodine and a 
synthetic polymer
Both have different physical characteristics that relate to the component parts and 
the iodine concentration of available iodine that is released when in use. Clinically 
iodine is indicated for wound cleansing, wound bed preparation (the stimulation and 
influence of specific cells involved with the immune system) and the prevention and 
management of wound infection.
3.10.3 Silver
Recently a number of dressings containing silver have become available, 
although silver and silver compounds have been routinely used in clinical practice as 
bactericidals for over a century. Silver interferes with the bacterial electron transport 
system and inhibits the multiplication of the bacteria. However, to achieve this, silver 
ions have to be able to enter a cell. The chemical bonding of silver with a 
sulphonamide antimicrobial - sulphadiazine - has resulted in the development of a 
safe broad-spectrum agent for topical use (eg Flamazine). In this formulation silver is 
released slowly from the transport medium in concentrations that are selectively toxic 
to micro-organisms such as bacteria and fungi. This type of silver product has been 
used successfully in the management of acute and chronic wounds.
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Products that can sustain the interaction of silver with micro-organisms in the 
exuding wound are likely to be more effective in preventing/controlling local 
infection as potentially more silver ions will be available to enter bacterial cells. This 
assumes that the concentration of silver in the solution is both correct and maintained.
3.11 Simarouba glauca
Patil Manasi S. (2011) conducted a Critical review on medicinally important oil 
yielding plant Laxmitaru (Simarouba glauca DC.). This study reveals the traditional 
uses of this particular medicinal plant as it is well known for the gastro intestinal 
diseases especially for the dysentery. It also gives a detailed information about the 
major chemically active constituents of the plant. The study summarizes 
Phytochemical, Ethnobotanical,  pharmacological, aspects and nursery practices of 
this medicinal plant.
Mishra S.R. (2012)  established a method for the production of Bio-diesel (Methyl 
Ester) from Simarouba Glauca Oil. By using methanol they trans-esterified the 
Simarouba glauca oil in the presence of KOH. After verifying all the parameters it 
was found to be as a good and viable alternative for the diesel fuel 
Iasmine A.B.S. Alves (2014) have conducted a detailed study on Simaroubaceae 
family its botany, chemical composition and biological activities. The study reveals 
the charecterisics and properties of almost all the plants of this particular family. 
Quassanoids are considered as the major chemically active constituents of this 
particular family, and the study also reveals the major uses of this particular family.
K. Santhana Lakshmi(2013)  studied the In vitro antibacterial, antioxidant, 
thrombolytic, haemolytic, activities and phytochemical analysis of simarouba glauca 
leaves extracts . The study was conducted by using various extracts. The methanolic 
extract showed maximum anti microbial activity, where as the heamolytic activity 
was found to be more in ethyl acetate extract. When compared to other extracts the 
chloroform exhibited maximum thrombolytic activity. 
T. G. Umesh (2014) evaluated the In vitro antioxidant potential, free radical 
scavenging and cytotoxic activity of simarouba gluaca leaves. The study reveals the 
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percentage of phenolic and flavanoid content in the plant. Among the various extracts 
the aqueous extract gives the maximum anti-oxidant activity. Cytotoxic effect (SCC9) 
was found to be more in the methanolic extract. 
Hélida M. L. Maranhao (2014) investigated Hepatoprotective effect of the aqueous 
extract of Simarouba amara Aublet (Simaroubaceae) stem and bark.  Carbon 
tetrachloride (CCl4) was used to induce Hepatic hamage in Rats. The treated groups  
decreased levels of liver markers and lipid peroxidation in all  given doses and  
showed increased  levels of catalase at doses 250 and and 500mg/kg. Immuno
histochemical tests shows positive signs of hepatocyte proliferation in all doses. It is 
suggested that the presence of catechins is responsible for these protective properties. 
Hence the study revealed that the plant can prevent the oxidative damage and it also 
increases the regenerative and reparative capacities of the liver.
Mail V.V (2014) reports the influence of various concentrations of fluoride on plant 
growth and metabolism. It was noticed that, the seedlings of Simarouba glauca shows 
tolerance to various concentrations of fluoride (5ppm, 10ppm, 25ppm, 50ppm, 
100ppm.). The stable growth of Simarouba glauca has been reflected changes in 
secondary metabolites. It was reported that the total polyphenols, anthocyanins and 
flavonoid contents were increased in response to fluoride stress. This might be due to 
induction of secondary metabolites under stress condition which will be beneficial for 
induction of fluoride stress tolerance. Thus, the induction of secondary metabolites 
due to stress will improve the bioactive potential of this medicinally important plant.
Rajamane, N.N.(2014) evaluated the effect of sodium chloride stress on polyphenol, 
flavonoid, anthocyanins contents and Lipid peroxidation of leaflets of Simarouba 
glauca.  The antioxidant capability of the plants was determined by measuring non-
enzymatic antioxidant activities such as total polyphenols and total flavonoids.
Anthocyanins and malondialdehyde content was also measured. Data indicate that
Simarouba glauca reacted to salt-induced oxidative stress by increasing non-
enzymatic antioxidant, defenses proportionally to the increasing of the stress imposed, 
and the total polyphenols, total flavonoids, anthocyanins and malondialdehyde 
contentwas found to be increased.
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4. PLANT PROFILE [41][49][50][51]
                   
                                                    Figure 4:  Simarouba glauca.
Plant name  : Simarouba glauca also known as Paradise tree 
Family         : Siamroubaceae
Synonyms   : Simarouba amara, Quassia simarouba, Zwingera amara, Picraena 
officinalis,
                       Simarouba medicinalis    
4.1 Vernacular  names:
English      : bitter ash, bitter damson princess tree, Simarouba, Paradise tree.
Spanish      : acajou blanc, daguilla, daguillo gavilan, juan, primero, laguilla, olivio, 
palo
Creole        : bwa blan, bwa fwenn, doliv fwenn.
French       : bois amer, bois blance, bois frene, bois negresse, quinquina d Europe.
Trade name: Simarouba, Dysentry bark, Mountain Damson, Acituno.
Tamil         :  Laxmi taru
4.2 Natural habitat and distribution
S.glauca DC. is indigenous to Southern Florida, the West Indies and 
Brazil. It is native to Bahamas, Costa Rica, Cuba, EI-Salvador, Guatemala, Haiti, 
Honduras, Jamaica, Mexico, Puertorico, united states of America. While exotic to 
India, Srilanka, Phillippines and Myanmar. It grows under tropical conditions in 
Central America spreading from Mexico to Panama Southern Florida as well as 
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Caribbean Islands. S. glauca was introduced in Kenya and Burundi in Africa in 1957.
It grows best in areas where the annual temperature ranges between 22-290c., but can 
tolerate a range of 18-340C. It prefers a mean annual rainfall in the range 2,000-
3,000mm, but tolerates 1,200-4,000mm, growing in areas with a distinct dry season 
and where there is no dry season. It prefers sandy soils in the wild where it is found 
on rocky, shallow calcareous soils of mountain slopes and ridges, as well as on the 
deeper soils of the ravines and alluvial plains
4.3 Reproductive biology:
The tree starts flowering and fruiting at about three years of age. Flowering is 
annual beginning in December and continuing up to February. The tree starts bearing 
when they are 4-6 years old and reach stability in production of another 4-5 years. The 
droplets (blackish purple in pink genotypes and brownish yellow in green genotypes) 
are ready for harvest by March/April. Season and duration of reproductive 
phenoperiods vary according to location and climate. Individuals fruits have a 
development and ripening period of 1-2 months. Fruits is ellipsoid drupe,2-2.5cm 
long, with thin hard cuticle and juicy fruit pulp.
4.4 Botanical description:
It is a large, evergreen dioecious tree with a broad crown that can reach a 
height of 42 metres tall, though is usually smaller. The straight, cylindrical, 
unbuttressed bole is up to 50 - 60cm in diameter, strongly tapered and frequently 
unbranched for 20 - 27metre. Leaves are pinnately compound, entire, petiolate, 
alternately arranged with 9-16 leaflets per leaf. New flush of leaves produced every 
year. Flowers are pale yellow in colour. Male and female flowers are produced on 
separate trees. So are unisexuals. Fruits are Drupes, oval, elongated, 1-5 inch in 
length, brightly coloured, green to purplish-black containing large seeds which are 
dispersed by vertebrates with fleshy fruit covering.
4.5 Part used:
Bark, flower, stems, seeds, leaves, roots.
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4.6 Chemical Constitutes:
QUASSINOIDS namely, Ailanthinone, Glaucarubinone, Holocanthone, 
Dehydroglaucarubinone, Benzoquinone, Canthin, Glaucarubine, Glaucarubolone, 
Simarubin, Melianone, Simaroubidin, Simarolide, Sitosterol, Tirucalla and 
Flavonoids.
4.7 Therapeutic Uses:
An infusion of the leaves or bark is considered to be astringent, a digestion 
and menstrual stimulant and an antiparasitic remedy. It is taken internally for Cancer,  
diarrhoea, dysentery, malaria, colitis, Hemorrhage, Anemia, Rheumatoid arthritis, 
Hepatitis, Hyperacidity, Dyspepsia, Fever, Ulcers and bleeding in alimentary system,; 
it is used externally for wounds and sores.
Materials and methods
Department of Pharmacology Page 39
5. MATERIALS AND METHODS
5.1 MATERIALS USED FOR THE STUDY
Table 4:  List of Instruments
Sl.No Insruments Manufacturer
1 Analytical weighing balance Shimadzu
2 Cooling centrifuge Remi
3 Deep freezer (-800C) Remi
4 Electric water bath Technico
5 Homogenizer Remi
6 Hot air oven Narang scientific works
7 HPTLC Camag
8 PH meter Eutech
9 Rotary evaporator IKA RV10
11 Ultra sonicator Soltec
12 UV spectrometer Pharmaspec UV-1700, Shimadzu
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5.2 CHEMICALS USED FOR THE STUDY
Table 5: List of Chemicals.
Sl. 
No
Chemical Manufacurer
1
2, 2’- azinobis (3-ethylbenzothiazoline-6-
sulfonic acid) diammonium salt (ABTS)
Himedia
2 5,5-dithiobis (2-nitro benzoic acid) DTNB Himedia
3 Ascorbic acid SISCO
4 Bovine serum albumin (BSA) SD-Fine chem
5 Chloramine T Himedia
6 1,1- diphenyl-2-picrylhydrazyl (DPPH) HIMEDIA
7 Folin-Ciocalteau reagent HIMEDIA
8 Gallic acid Zigma Aldrich
9 Glutathione reduced Himedia
10 Quercetin Himedia
11 Sodium azide Himedia
12 Thiobarbituric acid Himedia
13 Trichloro acetic acid Himedia
14 P-dimethylaminobenzaldehyde Himedia
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5.3 METHODS
5.3.1 PLANT COLLECTION AND AUTHENTICATION
The aerial part of the plant Simarouba glauca was collected from Alapuzha 
District of kerala and authenticated from the Botanical survey of India (BSI), southern 
circle, Coimbatore, Tamil Nadu. The authentication certificate number is No. 
BSI/SRC/5/23/2016/Tech/605. Soon after collection, the leaves were cleaned and 
shade dried. After drying, these leaves were crushed to a coarse powder, stored in air 
tight plastic containers for further use.
5.3.2 EXTRACTION OF THE PLANT MATERIAL[44]
The extraction is done by using Sohxlet apparatus. The coarse powder of the 
leaves was first extracted with petroleum ether. Obtained defatted material is again 
extracted with ethyl acetate and aqueous. After extraction the extracts were 
evaporated or concentrated by using rotary evaporator and dried at room temperature 
to give a viscous mass. The obtained crude extracts were weighed and stored at 40C 
for the further analysis.
5.3.3 QUALITATIVE PHYTOCHEMICAL ANALYSIS OF EASG AND 
AQSG.[52][53][54][55]
5.3.3.1 Preparation of test sample
A small quantity of the extract was dissolved in 5ml of distilled water and 
filtered. The filtrate was tested to detect the presence of various phytochemical 
constituents in the sample.
5.3.3.2 TEST FOR CARBOHYDRATES
ß Molisch’s test
Few drops of Molisch’s reagent was added to 2-3ml of filtrate, followed by 
addition of concentrated sulphuric acid along the sides of the test tube. Formation of 
violet colour ring at the junction of two liquids indicates the presence of 
carbohydrates.
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ß Fehling’s test
1ml Fehling’s-A (copper sulphate in distilled water) was added to 1ml of 
Fehling’s-B (potassium tartarate and sodium hydroxide in distilled water) solution, 
boiled for one minute. To this added 1ml of filtrate and heated gently. Formation of 
brick red precipitate indicates the presence of reducing sugars.
ß Benedict’s test
Few ml of filtrate was mixed with equal volume of Benedict’s reagent (alkaline 
solution containing cupric citrate complex) and heated in boiling water bath for 5min. 
Formation of reddish brown precipitate infers the presence of reducing sugars.
5.3.3.3 TEST FOR ALKALOIDS
Small amount of extract mixed with few ml of dilute hydrochloric acid. 
Shaken well and filtered. Following tests were performed with the obtained filtrate.
ß Dragendorff’s test
A few drops of Dragendorff’s reagent (potassium bismuth iodide solution)was 
added to 2-3ml of filtrate. Orange red precipitate indicates the presence of alkaloids.
ß Mayer’s test
A few drops of Mayer’s reagent (potassium mercuric iodide solution) was 
added to 2-3ml of filtrate. Cream (dull white) precipitate was formed.
ß Wagner’s test
A few drops of Wagner’s reagent (solution of iodine in potassium iodide)was 
added to 2-3ml of filtrate,. Reddish brown precipitate was obtained.
ß Hager’s test
A few drops of Hager’s reagent (Picric acid) was added to 2-3mlof filtrate. 
Yellow precipitate was obtained
5.3.3.4 TEST FOR TRITERPENOID
ß Libermann-Burchard test
A small quantity of extract was treated with few drops of acetic anhydride, followed 
by a few drops of concentrated sulphuric acid. A brown ring was formed at the 
junction of two layers and the upper layer turns green colour, infers the presence of 
phytosterols and formation of deep red colour indicates the presence of triterpenoids.
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ß Salkowski test
A small quantity of the extract was treated with chloroform and few drops of 
concentrated sulphuric acid and allowed to stand for few minutes. Yellow colour at 
the lower layer indicates the presence of triterpenoids.
5.3.3.5 TEST FOR GLYCOSIDES
ß Legal’s test
1ml of pyridine and 1ml of sodium nitroprusside was added to 1ml of extract.
Pink to red colour indicates the presence of glycosides.
ß Keller-Killiani test
Glacial acetic acid was added to 2ml extract, followed by the addition of trace 
quantity of ferric chloride and 2 to 3drops of concentrated sulphuric acid. Reddish 
brown colour appears at the junction of two liquid indicates the presence of cardiac 
glycosides.
ß Baljet test:
2ml of extract was addedto sodium picrate solution. Yellow to orange colour 
formation indicates the presence of glycosides.
5.3.3.6 TEST FOR STEROIDS AND STEROLS
ß Liebermann- Burchard reaction
2ml of extract was mixed with chloroform. To that mixture added 1-2ml of 
acetic anhydride and 2drops of concentrated sulphuric acid along the sides of the test 
tube. The solution becomes red, then blue and finally bluish green colour.
ß Salkowski reaction
2ml of extract was mixed with 2ml chloroform and 2ml concentrated sulphuric 
acid. Shaken well. Chloroform layer appears red and acid layer shows greenish yellow 
fluorescence.
5.3.3.7 TEST FOR PHENOLS
ß Ferric chloride test
1ml of the alcoholic solution of the extract was added to 2ml of distilled water 
followed by few drops of 10% ferric chloride. Formation of blue or green colour 
indicates the presence of phenols.
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ß Lead acetate test
Diluted 1ml of alcoholic solution of extract with 5ml distilled water and to this 
added few drops of 1% aqueous solution of lead acetate. Formation of yellow colour 
precipitate indicate the presence of phenols.
5.3.3.8 TEST FOR TANNINS
ß Lead acetate test
A few drop of lead acetate was added to 5ml of aqueous extract. Formation of
yellow or red colour precipitate indicates the presence of tannins.
5.3.3.9 TEST FOR SAPONINS
ß Foam Test:
1ml of test sample was diluted with 20ml of distilled water and shaken it in a 
graduated cylinder for 3minutes. Foam of 1cm after 10min indicates the presence of 
saponins.
ß Froth test:
5ml of test sample was added to sodium bicarbonate solution. After vigorous
shaking the mixture, kept it for 3minutes. A honey comb like froth formation 
indicates the presence of saponins.
5.3.3.10 TEST FOR FLAVONOIDS
ß Alkaline reagent test
A few drop of sodium hydroxide solution was added to the extract. Formation 
of an intense yellow colour, which turns to colourless on addition of few drops of 
dilute hydrochloric acid, indicates the presence of flavonoids.
ß Shinodas test [Magnesium hydrochloride reduction test]
Alcoholic solution of extract was treated with a small piece of magnesium 
ribbon and a few drops of concentrated HCl was added and heated. Appearance of 
crimson red or occasionally green to blue colour infers the presence of flavonoid.
5.3.3.11 TEST FOR PROTEINS AND AMINO ACIDS
ß Biuret test
3ml of test solution was added to 4% sodium hydroxide and few drops of 1% 
copper sulphate solution. Formation of violet colour indicates the presence of 
proteins.
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ß Ninhydrin test
A mixture of 3ml test solution and 3drops of 5% Ninhydrin solution was 
heated in a boiling water bath for 10min. Formation of purple or bluish colour 
indicates the presence of free amino acids. 
5.3.4 HIGH PERFOMANCE THIN-LAYER CHROMATOGRAHIC (HPTLC) 
METHOD FOR ESTIMATION OF FLAVONOIDS[56]
Standardization of plant materials and constituents is the need of the day. Also, 
the WHO has emphasized the need to ensure the quality of medicinal plant products 
using modern controlled techniques and applying suitable standards. 
Chromatographic fingerprinting techniques are the most significant methods which 
may be used for herbal drug analysis and for quality assurance. 
High-performance thin layer chromatography (HPTLC) based methods could be 
considered as a good alternative, as they are being explored as an important tool in 
routine drug analysis. Major advantage of HPTLC is its ability to analyze several 
samples simultaneously using a small quantity of mobile phase. HPTLC also offers 
better resolution, accuracy, less time consuming and low cost of analysis. 
Additionally, it minimizes exposure risks and significantly reduces disposal problems 
of toxic organic effluents, thus reducing possibilities of environment pollution. 
HPTLC also facilitates repeated detection of chromatogram with same or different 
parameters.
The basic principle of HPTLC is adsorption. Where the mobile phase used is 
non-polar and the stationary phase is polar. Chemical or active constituents present in 
the plant extract will move through the plate according to the relative solubility of the 
constituents in the two phases and will be separated. The non- polar compound will be 
eluted first and the more polar later. The compounds can be identified based on the Rf
value.
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Experimental condition:
ß Stationary phase : Aluminium plates precoated with Silica Gel 
60F254 (10×10×0.2mm thickness)
ß Mobile phase : Tolene:Ethyl acetate:Formic acid
:Methanol(3:6:1.6:0.4)
ß Sample for HPTLC : EASG, AQSG, and standard Quercetin, 
Rutin, Gallic acid, Apigenin And 
andrographolide solutions.
ß Sample application : Camag Linomat 5
ß Chamber type : Twin trough Chamber 10× 10cm
ß Chamber saturation : 5min
ß Development time : 30min
ß Development distanc : 7cm
ß Detection : Camag Scanner 3
ß Data system : win CATS Planar Chromatography 
Manager.
Instrumental Parameters
ß Number of track : 8
ß Band length : 6.0mm
ß Application position : 10mm
ß Solvent front position : 80.0mm
ß Solvent volume : 10ml
ß Position of first track : 10mm
ß Distance between tracks : 11.4mm
ß Scan start position Y : 5.0mm
ß Scan end position : 75.0mm
ß Slit dimension : 6.00 × 0.45mm, Micro
ß Optimized optical system : light
ß Scanning speed : 20mm/sec
ß Data resolution : 100μM/ step
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Measurement table:
ß Wavelength : 254nm
ß Lamp : D2 &W
ß Measurement : Remission
ß Measurement mode : Absorption
ß Optical filter : Second order
ß Detector mode : Automatic
Preparation of standard
Stock solutions of Standard compounds were prepared by dissolving 
accurately weighed 1mg of gallic acid, Rutin, Quercetin, Apigenin And 
andrographolide in 1ml of methanol (HPTLC grade), and stored at 40C. And 5µl of 
each standard were spotted on the HPTLC plate.
Preparation of Sample
Weighed accurately 1g of both ethyl acetate and aqueous extract and dissolved 
separately in 10ml of ethyl acetate and water. Each sample was then filtered by using 
Whatmann No.1 filter paper. 5µl of both extracts were spotted on the HPTLC plate.
Procedure:
The standards; gallic acid, Rutin, Quercetin, Apigenin And andrographolide
(5µl), EASG and AQSG were spotted in form of bands with a Camag microlite 
syringe on pre-coated Silica Gel glass plate 60F254 (10×10cm with 0.2mm thickness ) 
using a Camag Linomat 5 applicator. The plates were pre-washed with methanol and 
activated at 600c for 10min prior to chromatography. The sample loaded plate was 
kept in TLC twin trough developing chamber after chamber saturation with respective 
mobile phase. The optimized chamber saturation time for mobile phase was 5 min at 
room temperature. Linear ascending development was carried out and the plate was
developed in the respective mobile phase up to 7cm. The developed plate was then
dried by hot air to evaporate solvents from plate and also for the development of 
bands. The dried plate was observed under UV light at 254nm and 366nm and photo 
documentation was done. Densitometric scanning was performed on Camag TLC 
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scanner 3 in the absorbance mode at 280nm. The percentages of active constituents 
present in the both extracts were compared with that of standard.
5.3.5 QUANTIFICATION OF TOTAL PHENOLICS AND FLAVONOIDS[45][57]
5.3.5.1 ESTIMATION OF TOTAL PHENOLICS
Reagents
ß Folin-Ciocalteu’s reagent
ß Gallic acid (1mg/ml)
ß 20% sodium carbonate
Preparation of standard
Standard solution of was prepared by adding 10mg of accurately weighed 
Gallic acid in 10ml of distilled water.
Preparation of sample
10mg of the accurately weighed EASG and AQSG extracts were separately 
dissolved in 10ml ethanol and used for the estimation
.
Procedure
The total phenolic content of the EASG and AQSG were determined by Folin-
Ciocalteau assay method. To an aliquot 100μl of both EASG and AQSG (1mg/ml) or 
standard solution of Gallic acid (10, 20, 40, 60, 80, 100μg/ml) added 50μl of Folin-
ciocalteau reagent followed by 860μl of distilled water and the mixture is incubated 
for 5min at room temperature. 100μl of 20% sodium carbonate and 890μl of distilled 
water were added to make the final solution to 2ml. It was incubated for 30min in 
dark to complete the reaction. After that absorbance of the mixture was measured at 
725nm against blank. Distilled water was used as reagent blank. The tests were 
performed in triplicate to get mean the values. The total phenolic content was found 
out from the calibration curve of Gallic acid. And it was expressed as milligrams of 
Gallic acid equivalents (GAE) per gram of extract.
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5.3.5.2 ESTIMATION OF TOTAL FLAVONOIDS
Reagents
∑ Ethanol
∑ 10% aluminium chloride
∑ 1M Potassium acetate
Preparation of standard
Standard solution of was prepared by adding 10mg of accurately weighed 
Quercetin in 10ml of ethanol.
Preparion of sample
10mg of the accurately weighed EASG and AQSG extracts were separately 
dissolved in 10ml ethanol and used for the estimation.
Procedure
The total flavonoid content of the EASG ad AQSG was determined by using 
Aluminium chloride colorimetric method. To an aliquot of 1ml of extract (1mg/ml) or 
standard solutions of Quercetin (10, 20, 40, 60, 80, 100μg/ml) methanol was added
separately to make up the solution upto 2ml.  The resulting mixture was treated with 
0.1ml of 10% aluminium chloride, 0.1ml of 1M potassium acetate and 2.8ml of 
distilled water. Shaken well and incubated at room temperature for 30 minutes. The 
absorbance was measured at 415nm against blank, where a solution of 2ml ethanol, 
0.1ml potassium acetate, 2.8ml distilled water and 0.1ml of aluminium chloride serve 
as blank solution. The total flavonoid content was determined from the standard 
Quercetin calibration curve. And it was expressed as milligrams of Quercetin 
equivalents (QE) per gram of extract.
5.3.6 INVITRO-ANTIOXIDANT STUDY OF EASG AND AQSG
5.3.6.1 DPPH Free Radical Scavenging Assay[58]
Principle
The DPPH [1, 1-diphenyl-2-picrylhydrazyl (α, α-diphenyl-β-picrylhydrazyl)]
assay method is based on the reduction of DPPH, a stable free radical. The free 
radical DPPH with an odd electron gives a maximum absorption at 517nm (purple 
colour). When Antioxidants react with DPPH, which is a stable free radical becomes 
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paired off in the presence of a hydrogen donor (e.g., a free radicalscavenging 
antioxidant) and is reduced to the DPPHH and as consequence the absorbance’s 
decreased from the DPPH. DPPH radical is a stable radical by virtue of the 
delocalization of the spare electron over the molecule as a whole, so that the 
molecules do not dimerise, as would be the case with most other free radicals. The 
delocalization also gives rise to the deep violet colour, characterized by an absorption 
band in ethanol/methanol solution centred at about 520nm Radical to the DPPH-H 
form, results in decolorization (yellow colour) with respect to the number of electrons 
captured. More the decolorization more is the reducing ability. This test has been the 
most accepted model for evaluating the free radical scavenging activity of any new 
drug. When a solution of DPPH is mixed with that of a substance that can donate a 
hydrogen atom, then this gives rise to the reduced form (Diphenylpicrylhydrazine; 
non radical) with the loss of this violet colour (although there would be expected to be 
a residual pale yellow colour from the picryl group still present).
Procedure
The method adopted here is Blois method. Where by using the stable DPPH 
radical, the antioxidant capacity of the extract was measured in terms of hydrogen 
donating or radical scavenging ability. 1ml of 0.3mM solution of DPPH in ethanol 
was added to various concentrations of sample (10, 20, 40, 60,80, 100 μg/ml) and the 
reference compound (5, 10, 15, 20, 25 and 30 μg/ml), shaken vigorously, and left to 
stand in the dark at room temperature. After 30 min absorbance was measured at 
517nm against a blank. Quercetin was used as Reference compound. A control 
reaction was also carried out without the test sample. All the tests were performed in 
triplicate in order to get the mean values. The percentage of inhibition was calculated 
by comparing the absorbance values of the control and test samples. Free radical
scavenging activity was expressed as percentage inhibition (I%) and calculated using 
the following equation:
+ AH +A˙
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Percentage inhibition (I%) = (Abs control- Abs sample /Abs control) X 100
Different sample concentrations were used in order to obtain calibration 
curves and to calculate the IC50 values. (IC50 - concentration required to obtain a 
50% radical scavenging activity).
5.3.6.2 ABTS Assay[59][60]
Principle
A method for the screening of antioxidant activity is reported as a 
decolorization assay applicable to both lipophilic and hydrophilic antioxidants, 
including flavonoids, hydroxycinnamates, carotenoids, and plasma antioxidants. The 
pre-formed radical monocation of 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic 
acid) (ABTS*+) is generated by oxidation of ABTS with potassium persulfate and is 
reduced in the presence of such hydrogen-donating antioxidants present in the sample. 
The influences of both the concentration of antioxidant and duration of reaction on the 
inhibition of the radical cation absorption are taken into account when determining the 
antioxidant activity. Chemistry involves the direct generation of the ABTS radical 
monocation with no involvement of an intermediary radical. It is a decolorization 
assay; thus the radical cation is pre-formed prior to addition of antioxidant test 
systems, rather than the generation of the radical taking place continually in the 
presence of the antioxidant. An antioxidant with an ability to donate a hydrogen atom 
will quench the stable free radical and inhibits the absorption of the radical cation 
which has characteristic long-wavelength absorption spectrum showing maxima at 
660,734, and 820nm.The relatively stable ABTS radical has a green colour and is 
quantified spectrometrically at 734nm. It is applicable to both aqueous and lipophilic 
systems.
Procedure
ABTS radical scavenging activity of the extract was measured by Rice-Evans 
method. ABTS was dissolved in water to a 7mM concentration. ABTS radical cation 
(ABTS+) was produced by reacting ABTS stock solution with 2.45mM potassium 
persulfate and allowing the mixture to stand in the dark at room temperature for 12-
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16h before use. The radical was stable in this form for more than 2 days when stored 
in the dark at room temperature. For the study, ABTS solution was diluted with 
phosphate buffer saline pH 7.4 (PBS) to an absorbance of 0.70 (± 0.02) at 734nm and 
equilibrated at 300C. After addition of 1ml of diluted ABTS solution to various 
concentrations of sample or reference compound (Quercetin), the reaction mixture 
was incubated for 6min and then absorbance was measured at 734 nm against a blank. 
A control reaction was carried out without the sample. All the tests were performed in 
triplicate in order to get the mean values. The percentage inhibition of ABTS+ by the 
sample was calculated according to the formula:
Percentage inhibition (I %) = (Abs control- Abs sample /Abs control) X 100
Different sample concentrations were used in order to obtain calibration 
curves and to calculate the EC50 values. (EC50 - concentration required to obtain a 
50% radical scavenging activity).
5.3.7ANTI-MICROBIAL ACTIVITY OF EASG AND AQSG[44]
5.3.7.1 Anti –bacterial study of EASG and AQSG
Preparation of inoculums
The inoculums for the experiment were prepared in fresh Nutrient broth from 
the preserved slant culture. The turbidity of the culture can be adjusted by the addition 
of broth or sterile saline (if it is excessive) or by further incubation to get the 
required turbidity, And the newly prepared inoculums were standardized by adjusting 
the turbidity of the culture to that of McFarland standards.
Preparation of sterile swabs
Cotton wool swab on wooden applicator or plastics were prepared and 
sterilized by autoclaving or by dry heat (only for the wooden swabs). It was sterilized 
by packing the swabs in culture tubes, papers or tins etc.
Sterilization of forceps
Forceps can be sterilized by dipping in alcohol and burning off the alcohol.
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Experiment
The standardized inoculums is inoculated in the sterilized plates prepared 
earlier (aseptically) by dipping a sterile in the inoculums removing the excess of 
inoculums by passing and rotating the swab firmly against the side of the culture tube 
above the level of the liquid and finally streaking the swab all over the surface of the 
medium 3 times rotating the plate through an angle of 60º after each application. 
Finally pass the swab round the edge of the agar surface. Leave the inoculums to dry 
at room temperature with the lid closed.  The sterile discs are soaked overnight in 
sample solutions, EASG and AQSG. Each Petri dish is divided into 3 parts. First and 
second compartment were loaded with sample disc such as EASG and AQSG (100µg) 
and Std Ciprofloxacin disc (10µg), is placed on the fourth compartment of the plate 
with the help of sterile forceps. After that petri dishes are placed in the refrigerator at 
4º C or at room temperature for 1 hour for diffusion. Incubate at 37 º C for 24 hours. 
Observe the zone of inhibition produced by different samples. Measure it using a 
scale and record the average of two diameters of each zone of inhibition.
Table 6: Bacterial strain used for the study with NCIM
Si no organisom strain NCIM
1
Gram + ve bacteria
Staphylococcus lentus 2169
2 Staphylococcus albus 2178
3 Staphylococcus aureus 2079
4 Bacillus subtilis 2063
5 Bacillus lentus 2018
6
Gram –ve bacteria
Vibrio cholerae 1738
7 Corynebacterium 2640
8 E-coli 2065
9 klebsilla 2707
10 pseudomonasaeurogenosa 2200
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5.3.7.2 Anti fungal activity of EASG and AQSG
Procedure
Preparation of inoculums
The inoculums for this particular experiment were prepared in fresh sabouraud 
Dextrose broth from preserved slant culture. The turbidity of the culture can be 
adjusted by the addition of broth or sterile saline (if it is excessive) or by further 
incubation to get the required turbidity, And the newly prepared inoculums were 
standardized by adjusting the turbidity of the culture to that of McFarland standards.
Preparation of sterile swabs
Cotton wool swab on wooden applicator or plastics were prepared and 
sterilized by autoclaving or by dry heat (only for the wooden swabs). It was sterilized 
by packing the swabs in culture tubes, papers or tins etc.
Sterilization of forceps
Forceps can be sterilized by dipping in alcohol and burning off the alcohol.
Experiment
The standardized inoculums is inoculated in the sterilized plates prepared 
earlier (aseptically) by dipping a sterile in the inoculums removing the excess of 
inoculums by passing and rotating the swab firmly against the side of the culture tube 
above the level of the liquid and finally streaking the swab all over the surface of the 
medium 3 times rotating the plate through an angle of 60º after each application. 
Finally pass the swab round the edge of the agar surface. Leave the inoculums to dry 
at room temperature with the lid closed.  The sterile discs are soaked overnight in 
sample solutions, EASG and AQSG. Each Petri dish is divided into 3 parts. First and 
second compartment were loaded with sample disc such as EASG and AQSG (100µg) 
and Std Clotrimazole disc (10µg), is placed on the fourth compartment of the plate 
with the help of sterile forceps. After that petri dishes are placed in the refrigerator at 
4ºC or at room temperature for 1 hour for diffusion. Incubate at 37 ºC for 24 hours. 
Observe the zone of inhibition produced by different samples. Measure it using a 
scale and record the average of two diameters of each zone of inhibition.
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Table 7; Fungal strain used for the study with MTCC
Si no Fungi strains used MTCC
1 A.fumigatus 1811
2 M.purpureas 1090
3 A. paraticus 2796
4 Candida albicans 3100
5 A.niger 1344
5.3.7.3 DETERMINATION OF MINIMUM INHIBITORY CONCENTRATION
OF EASG and AQSG[61][62]
The minimum inhibitory concentration (MIC) is the lowest concentration of a 
chemical that prevents the visible growth of the organism.ie, the lowest concentration 
at which it has bacteriostatic activity.
5.3.7.3.1 Preparation of test drug:
The selected test drugs were prepared in DMSO at a concentration 1000µg/ml 
5.3.7.3.2 Preparation of inoculum:
Staphylococcus albus , Coryne bacterium and candida albicans were the
strains of organisms selected for the study. Overnight culture are grown at 370C
Kirby- Bauer procedure and diluted to Muller Hinton Broth and Sabouraud Dextrose 
Broth for bacterial and fungal strains respectively. This overnight culture was diluted 
to 10-2.
Inoculation
1. The sterile tubes were labeled 1-8 and 8th tube was taken as control.
2. 1ml of Muller Hinton Broth was transferred to all tube.
3. 1ml of drug solution was added to 1st tube and mixed well.
4. From the 1st tube transfer 1ml of solution to the 2nd tube and was repeated up 
to 7th tube.
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5. From the 7th tube 1ml of solution was pipetted out and discarded.
6. 0.01ml of culture was added to all the test tubes.
7. All the tubes were incubated at 370C for 18-24hrs.
8. After incubation observe the turbidity by visually
9. The highest dilution without growth is the minimal inhibitory concentration.
5.3.8 DETERMINATION OF IN VITRO CYTOTOXICITY PROPERTIESOF 
EASG AND AQSG ON CULTURED FIBROBLAST CELLS BY MTT 
ASSAY[63][64]
5.3.8.1 Chemicals
3-(4,5–dimethyl thiazol–2–yl)–5–diphenyltetrazolium bromide (MTT), Fetal 
Bovine serum (FBS), Phosphate Buffered Saline (PBS), Modified Eagle’s Medium 
(MEM) and Trypsin were obtained from Sigma Aldrich Co, St Louis, USA. EDTA, 
Glucose and antibiotics from Hi-Media Laboratories Ltd., Mumbai. Dimethyl 
Sulfoxide (DMSO) and Propanol from E.Merck Ltd., Mumbai, India.
5.3.8.2 Cell lines and Culture medium
Fibroblast cell line was procured from National Centre for Cell Sciences 
(NCCS), Pune, India. Stock cells were cultured in MEM supplemented with 10% 
inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 
mg/ml) and amphotericin B (5 mg/ml) in an humidified atmosphere of 5% CO2 at 37∞C 
until confluent. The cells were dissociated with Trypsin solution (0.2% trypsin, 0.02% 
EDTA in PBS). The stock cultures were grown in 25 cm2 culture flasks and all 
experiments were carried out in 96 microtitre plates (Tarsons India Pvt. Ltd., Kolkata, 
India).
5.3.8.3 Preparation of Test Solutions
For Cytotoxicity studies, each weighed test drugs were separately dissolved in 
distilled DMSO and volume was made up with MEM supplemented with 2% 
inactivated FBS to obtain a stock solution of 1mg/ml concentration and sterilized by 
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filtration. Serial two fold dilutions were prepared from this for carrying out cytotoxic 
studies.
5.3.8.4 Determination of cell viability by MTT Assay
Principle:
The ability of the cells to survive a toxic insult has been the basis of most 
Cytotoxicity assays. This assay is based on the assumption that dead cells or their 
products do not reduce tetrazolium. The assay depends both on the number of cells 
present and on the mitochondrial activity per cell. The principle involved is the 
cleavage of tetrazolium salt 3-(4, 5 dimethyl thiazole-2-yl)-2, 5-diphenyl tetrazolium 
bromide (MTT) into a blue coloured product (formazan) by mitochondrial enzyme 
succinate dehydrogenase. The number of cells was found to be proportional to the 
extent of formazan production by the cells used.
Procedure:
The monolayer cell culture was trypsinized and the cell count was adjusted to 
1.0 x 105 cells/ml using MEM containing 10% FBS. To each well of the 96 well
microtitre plate, 0.1 ml of the diluted cell suspension (approximately 10,000 cells) 
was added. After 24 h, when a partial monolayer was formed, the supernatant was 
flicked off, washed the monolayer once with medium and 100 ml of different test 
concentrations of test drugs were added on to the partial monolayer in microtitre 
plates. The plates were then incubated at 37o C for 3 days in 5% CO2 atmosphere, and 
microscopic examination was carried out and observations were noted every 24 h 
interval. After 72 h, the drug solutions in the wells were discarded and 50 ml of MTT 
in PBS was added to each well. The plates were gently shaken and incubated for 3 h 
at 37o C in 5% CO2 atmosphere. The supernatant was removed and 100 ml of propanol 
was added and the plates were gently shaken to solubilize the formed formazan. The 
absorbance was measured using a microplate reader at a wavelength of 540 nm. The 
percentage growth inhibition was calculated using the following formula and 
concentration of test drug needed to inhibit cell growth by 50% (CTC50) values is 
generated from the dose-response curves for each cell line.
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5.3.9. PHARMACOLOGICAL EVALUATION OF EASG AND AQSG
5.3.9.1 ACUTE TOXICITY STUDY:[65]
Based on previously conducted study of Simarouba glauca, the dose was 
selected.
5.3.9.2 ANIMALS AND MANAGEMENT
Female wistar rats of 6-8 weeks old and 160-180g body weight were offered 
by KMCH College of pharmacy, Coimbatore. All rats were kept at room temperature 
and allowed to accommodate in standard conditions at 12-hr light and 12-hr dark 
cycle in the animal house. Animals were fed with commercial pellet diet and water ad 
libitum freely throughout the study. The experimental procedure was approved by 
IAEC (Institutional animal ethical committee of KMCH, governed by CPCSEA, 
Government of India. Proposal number: KMCRET/ M.PHARM/04/2015-16
5.3.9.3 DRUG:
Povidone Iodine and silver sulfadiazine Ointments were used as standard drug. 
The ointments were applied topically over the wound area.
5.3.9.4 PREPARATION OF EXTRAT
Both EASG and AQSG were formulated to ointment (1%). And it is applied 
topically over the wound area.
5.3.9.4.1 PREPARATION OF SIMPLE OINTMENT BASE[66]
Ingrediants:
Wool fat 50g
Hard paraffin 50g
Cetostearyl alcohol 50g
White soft paraffin 850g
Type of preparation: Absorption ointment base
Procedure:
Hard paraffin and cetostearyl alcohol taken in a china dish kept on water-bath
at 700C. Wool fat and white soft paraffin are added to this mixture and stirred until all
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the ingredients are melted. If required decanted or strained and stirred until cold and
packed in suitable container.
1% of EASG AND AQSG were separately mixed with the above prepared simple
ointment base.
5.3.8.5 EXPERIMENTAL MODELS
5.3.8.5.1 EVALUATION OF WOUND HEALING EFFECT OF EASG AND 
AQSG IN EXCISION WOUND MODEL
Rats were divided into 5 groups each containing 6 animals as follows.
Table 8: Experimental design for excision wound model
GROUP
GROUP 
SPECIFICATION
INTERVENTION
Group I Control Untreated
Group II Simple ointment base
Only with simple 
ointment base
Group III Standard Povidone iodine 5%
Group IV Test 1 EASG ointment 1%
Group V Test 2 AQSG ointment 1%
INDUCTION OF WOUND[67]
On wounding day the rats were anaesthetized prior to creation of the wounds,
by ether anaesthesia. The dorsal fur of the animal was shaved with an electric clipper 
and the area of the wound to be created was outlined on the back of the animals with 
methylene blue using a circular stainless steel stencil. A full thickness of the excision 
wound of 1.5cm in width (circular area 2.25cm2) created along the markings using 
toothed forceps, a surgical blade and pointed scissors. The entire wound left open. All 
the surgical interventions were carried out under sterile condition. After 24h of wound
creation, the ointments was applied gently to cover the wounded area once daily until
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complete healing Wound area and wound contraction, epithelializtion period and
hydroxyproline content were monitored.
5.3.8.5.2 EVALUATION OF WOUND HEALING EFFECT OF EASG AND 
AQSG IN BURN WOUND MODEL 
Rats were divided into 5 groups each containing 6 animals as follows.
Table 9: Experimental design for burn wound model
GROUP
GROUP 
SPECIFICATION
INTERVENTION
Group I Control Untreated
Group II Simple ointment base
Only with simple 
ointment base
Group III Standard Silver sulfadiazine 5%
Group IV Test 1 EASG ointment 1%
Group V Test 2 AQSG ointment 1%
INDUCTION OF BURN WOUND[68]
On wounding day the rats were anaesthetized prior to creation of the wounds,
by ethr anaesthesia. The dorsal fur of the animal was shaved with an electric clipper 
and the area of the wound to be created was outlined on the back of the animals with 
methylene blue using a circular stainless steel stencil. A partial thickness burn was 
made by putting a hot plate at a temperature of 840c on the prepared area for 30 sec 
under sterile condition. The burnt area was measured immediately after the burn and 
on 3rd, 5th , 7th , 10th , 14th and 21st day after burn injury. After 24h of wound creation,
the ointment was applied gently to cover the wounded area once daily until complete 
healing achieved. Wound area and wound contraction, epithelializtion period and
hydroxyproline content were monitored.
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5.3.8.5.3 EVALUATION OF WOUND HEALING EFFECT OF EASG AND 
AQSG IN INFECTED EXCISSION WOUND MODEL
Rats were divided into 5 groups each containing 6 animals as follows.
Table 10: Experimental design for infected excision wound model
GROUP
GROUP 
SPECIFICATION
INTERVENTION
Group I Control Untreated
Group II Simple ointment base
Only with simple 
ointment base
Group III Standard Silver sulfadiazine 5%
Group IV Test 1 EASG ointment 1%
Group V Test 2 AQSG ointment 1%
Selection of micro-organism:
The organism selected for inducing the infected model is based on the MIC 
repots. Where the Staphylococcus albus showed good MIC value.
INDUCTION OF INFECTED EXCISION WOUND MODEL[69]
On wounding day the rats were anaesthetized by ether anesthesia prior to 
creation of the wounds. The dorsal fur of the animal was shaved with an electric 
clipper and the area of the wound to be created was outlined on the back of the 
animals with methylene blue using a circular stainless steel stencil. A full thickness of 
the excision wound of 1.5cm in width (circular area 2.25cm2) created along the 
markings using toothed forceps, a surgical blade and pointed scissors (Figure 1). 
Infected model created by using 0.1mL of saline containing 106 colony forming units
(CFU)/mL of Staphylococcus albus suspension, where the solution intradermally 
injected on the wounded area. The entire wound left. All the surgical interventions 
were carried out under sterile condition. After 72h of wound creation, the ointments 
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were applied gently to cover the wounded area once daily until complete healing
achieved. Wound area and wound contraction, epithelializtion period and
hydroxyproline content were monitored.
5.3.8.6 ESTIMATION OF PARAMETERS
5.3.8.6.1 Measurement of wound contraction[70]
The progression of wound healing was judged by the periodic assessment of 
the contraction of excision wounds. Wound contraction was monitored by tracing the
outline of the wound on tracing sheet and then using graph sheet to calculate the area 
of the wound size. All animals in each group were monitored until complete healing 
of wounds occurred and the day at which each
wound healed was recorded. Mean of all healed wounds was determined.
Percent wound contraction =  healed area   × 100
total area
5.3.8.6.1 Estimation of hydroxyproline [71][72]
Principle
The procedure is based on alkaline hydrolysis of the tissue homogenate and 
subsequent determination of the free hydroxyproline for the production of a pyrole. 
The addition of Ehrlich's reagent resulted in the formation of a chromophore that can 
be measured at 557nm. Optimal assay conditions were determined using tissue
homogenate and purified acid soluble collagen along with standard hydroxyproline. 
Critical parameters such as the amount of chloramine-T, sodium hydroxide, p-
dimethylaminobenzaldehyde, pH of the reaction buffer, and length of oxidation time 
were observed to obtain satisfactory results.
Procedure
Known amount of tissue (50mg) was taken in glass tubes and 4ml of 6N HCl 
was added to each tube to hydrolyse the tissue sample. The glass tubes were sealed
and were incubated for 22 hours. The tubes are then opened and the contents are 
decanted into a china dish. HCl was then removed by evaporation and the residue was 
dissolved in water and made up to known volume (10ml) using a standard flask. A 
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series of standards were prepared containing 20-200μg of hydroxyproline with afinal 
volume of 2ml. One millilitre of the hydrolysed tissue samples was used to estimate 
the contents of hydroxyproline. Hydroxyproline oxidation was initiated by adding 1ml 
of chloramine-T to each tube in a predetermined sequence. The tube content were 
mixed by shaking a few minutes and allowed to stand for 20min at room temperature.
Chloramine-T was then destroyed by adding 1ml of perchloric acid to each tube in the 
same order as before. The contents were mixed and allowed to stand for 5min. Finally 
1ml of p-Dimethyl aminobenzaldehyde solution was added and the mixture was 
shaken well. Tubes were
placed in a 60°C water bath for 20min and then cooled in tap water for 5min. The 
colour developed was read spectrophotometrically at 557nm. Hydroxyproline value
was determined from the standard curve.
5.3.8.6.3 Estimation of hexosamine [71] [73]
Principle
The method was based on the observation that in alkaline solution at 100°C, 
the amino sugars react with acetyl acetone to form chromogenic material which gives
a chromophore or chromophores on treatment in acid solution with ethanolic p-
dimethyl amino benzaldehyde. The method described is suitable for the estimation 
only for free amino sugars where a determination is carried to ascertain the amino 
sugar content of a polysaccharide or other material of high molecular weight. Any 
amino sugar units remaining as oligosaccharide or substituted amino sugar gives less 
color per unit weight of amino sugar than that found for free amino sugar. Therefore it 
is essential that the hydrolysis of granulation tissue is done without destruction of the 
amino sugar.
Procedure
Tissue samples (50mg) were hydrolysed with 2N HCL (5ml) at 100°C for 6 
hrs. Hydrochloric acid was then removed by evaporation, then the residue was 
dissolved in water and made up to a known volume (10ml) using a standard flask.
Aliquots containing 10-50mg hexosamine were treated with 1ml of freshly prepared 
2% acetyl acetone in 0.5M sodium carbonate in capped tubes and kept in boiling 
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water bath for 15min. After cooling in tap water, 5ml of 95% ethanol and 1ml of 
Ehrlich's reagent (1.33% Dimethyl amino benzaldehyde in 1:1 ethanol: concentrated 
hydrochloric acid mixture) were added and mixed thoroughly. The purple red colour 
developed was read after 30 min at 530 nm. Water blank and standard glucosamine 
solution of various concentrations were also treated similarly to get a standard curve.
5.3.8.6.4 Estimation of total protein[74]
Total protein content of the granular tissue was determined by following 
Bradford (1976) method.
Reagents
· Alkaline copper reagent
· Solution A: 2% sodium carbonate in 0.1 N NaOH.
· Solution B: 0.5% copper sulphate in 1% sodium potassium tartarate
· Solution C: 50ml of solution A was mixed with 1 ml of solution B just before 
use.
· Folin’s phenol reagent (commercial reagent, 1:2 dilutions) Bovine serum 
albumin (BSA).
Principle:
This method involves two steps;
Step: 1-protein binds with copper in alkaline medium and reduces it into cu++.
Step: 2- the cu++ formed catalyses the oxidation reaction of aromatic amino acids by
reducing phosphomolybdotungstate to heteropolymolybdanum, which leads to the
formation of blue colour and absorbance was measured at 640nm.
Procedure:
0.1 ml homogenate was made up to 1ml with distilled water and to this; 5ml of 
alkaline solution was added, mixed well and allowed to stand for 10min. Then a 
volume of 0.5ml Folin’s reagent was added, mixed well and incubated at room 
temperature for another 10min. The blue colour developed was measured at 660nm 
against blank. Bovine serum albumin (1mg/ml) served as the standard and form the 
standard graph obtained; the amount of protein in the sample was calculated and 
expressed as mg/100mg tissue
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5.3.8.6.5 Estimation of uronic acid[71][75]
Principle
The galacturonic acid content of the hydrolyzed sample is quantified 
colorimetrically using a modification of the Cu reduction procedure originally 
described by Avigad and Milner. This modification, substituting the commonly used 
Folin-Ciocalteau reagent for the arsenic containing Nelson reagent, gives a response 
that is linear, sensitive, and selective for uronic acids over neutral sugars. This method 
also avoids the use of concentrated acids needed for the commonly used m-
phenylphenol method. This combined enzymatic and colorimetric procedure correctly 
determined the galacturonic acid and methanol content of purified sample. In both 
cases good agreement was obtained between this method and commonly used 
methods.
Procedure
A buffered copper solution was prepared by adding 23.2g NaCl, 3.2g sodium 
acetate, and 1.0mL glacial acetic acid to 80mL water. Once dissolved, 0.5 g CuSO4 is 
added, the pH adjusted to 4.8 with NaOH, and the final volume brought to 100mL. 
This solution is stable for weeks at room temperature. For the assay, equal volumes of 
this solution and the sample are mixed, giving final reagent concentrations in the 
assay of 2 M NaCl, 0.2M acetate, and 10mM CuSO4. In our standard assay, sample 
and assay solution volumes of 0.1mL each are mixed in test tubes, then the tubes are 
covered with glass marbles and placed in an aluminum heating block at 100 C. A 
diluted Folin–Ciocalteau reagent is then prepared by mixing 1mL of 2N Folin–
Ciocalteau with 39mL of water. After 40min, the samples are removed from the heat 
and 8 volumes (0.8mL in our standard assay) of the 40-fold diluted Folin–Ciocalteau 
reagent is added. A colored product forms immediately; absorbance was measured at 
750nm. Where the BCA reagent was used the procedure was the same, except instead 
of adding the diluted Folin– Ciocalteau reagent, 0.8mL of solution ‘‘A” from the 
procedure described in Waffenschmidt and Jaenicke, containing 5.0mM BCA in pH 
10.1 carbonate buffer, was added. Absorbance was measured at 560nm.
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5.3.8.6.6 Tensile strength[76][77]
Principle
Tensile strength is the resistance to break, under tension. It indicates how 
much the repaired tissue resists breakage under tension and may indicate in part the 
quality of repaired tissue. The healed rat skin was used for the test. The strength of 
the tissue was represented in gram.
Procedure
The tensile strength of the samples was tested using DAK SYSTEM BENCH. 
Speed was set at 100mm per minute and the load cell used was of 500kg. The jaws of 
the tensile tester were set 50mm, apart for the samples. The test specimen was 
clamped in the jaws and the machine was run at the rate of 100±2mm/min. until the 
specimens tore apart. The highest load reached was recorded when the sample was 
subjected to breaking. The distance between the jaws when rapture of the test 
specimen occurred was noted.
5.3.8.7 IN VIVO ANTIOXIDANT ACTIVITY[78][79]
Preparation of tissue homogenate
For the estimation of non-enzymatic and enzymatic antioxidants, tissue was 
minced and homogenized (10% w/v) in 0.1M saline phosphate buffer (pH 7.4) and 
centrifuged for 10min and the resulting supernatant was used for enzyme assays.
5.3.8.7.1ENZYMATIC ANYI-OXIDANT ACTIVITY
5.3.8.7.1.1 ESTIMATION OF CATALASE (CAT)[80]
Reagents
∑ Dichromate acetic acid reagent (5% potassium dichromate + glacial acetic acid
were mixed at 1: 3 ratio (v/v).
∑ 0.01M Phosphate buffer (pH-7.0).
∑ 0.2M hydrogen peroxide.
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Principle:
The normal antioxidant activity of the enzyme catalase is due to acceleration 
of decomposition of hydrogen peroxide to water and oxygen. This method is based on
the principle that by measuring the rate of decomposition of hydrogen peroxide by the 
enzyme catalase spectrophotometrically at 570 nm, since hydrogen peroxide has the 
absorbance at this range.
2H2O2 H2O + O2
Procedure:
To 1ml of tissue homogenate 4ml of hydrogen peroxide and 5ml of phosphate
buffer was added and mixed well. From this, 1ml of solution was taken and mixed
with dichromate acetic acid reagent and allowed to incubate for 30min at room
temperature. The absorbance was measured at 570nm. The activity of catalase was
expressed as μmole of H2O2 consumed /min/mg protein.
5.3.8.7.1.2 ESTIMATION OF SUPEROXIDE DISMUTASE (SOD)[81][82]
Principle:
Pyrogallol autoxidizes rapidly in aqueous solution, where the reaction will be 
faster at higher pH, and leads to the formation of several intermediate products. Thus 
the solution first becomes yellow-brown with a spectrum showing a shoulder between 
400 and 425nm. Molecular oxygen, carrying two unpaired electrons with parallel 
spins, has a preference for univalent reduction because spin restrictions arise when 
reduction with electron pairs is attempted. The recently discovered enzyme 
superoxide dismutase rapidly dismutases univalently reduced oxygen O2.
- i.e., the 
superoxide anion radical (2O2.
- + 2 H+ O2+ H2O2). The enzyme has proven to be 
a useful probe for studying the participation of the radical in reactions involving 
oxygen such as autoxidations. Thus O2
-. has been shown to be involved in the 
autoxidation of e.g. sulphite, adrenalin  and 6-hydroxydopamine.
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Procedure
This method might be used for determination of antioxidant activity of a 
sample, and it was described by McCord and Fridovich. 5% of tissue homoginate was
added to 75mM, 30mM, and 2mM from Tris-HCL (pH 8.2), EDTA, and pyrogallol 
respectively. Then, the absorbance was measured at 420nm. The percentage of 
inhibition was calculated depending on that the ability of enzyme to inhibit of 
oxidation. So, any changes might be happened on the absorbance, it will give a clear 
picture on the ability of enzyme activity to prevent oxidation.
5.3.8.7.2 NON ENZYMATIC ANTIOXIDANT ACTIVITY
5.3.8.7.2.1 ESTIMATION OF REDUCED GLUTATHIONE (GSH)[83]
Reagents
· 5% TCA
· 0.6mM 5,5’-dithiobis-2-nitrobenzoic acid ( DTNB) in 0.2M sodium
phosphate
· 0.2M Phosphate buffer, pH 8.0
Principle:
DTNB known as Ellman’s reagent was developed for the detection of thiol
compounds. DTNB and sulfhydryl groups present in glutathione (GSH) react to
generate 2-nitro-5- thiobenzoic acid and glutathione disulfide (GSSG). Since 2-nitro-
5-thiobenzoic acid is a yellow coloured product, GSH concentration in a sample
solution can be determined by the measurement at 412nm [73]
Procedure
To 1ml of the homogenate, 1ml of the TCA solution was added and 
centrifuged. The supernatant was collected and the precipitate formed was removed. 
To 0.5ml of supernatant 2ml of DTNB was added, the volume was made up to 3ml 
with phosphate buffer. Then absorbance was read at 412nm. The amount of 
glutathione was expressed as μg/mg protein.
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5.3.8.7.3 DETERMINATION OF LIPID PEROXIDATION[84]
Reagents
· Thiobarbituric acid 0.37%
· 0.25N HCL
· 15% TCA
Principle:
This assay is based on the reaction between Thiobarbituric acid with
malonyldialdehyde which is formed as a result of polyunsaturated fatty acid
oxidation. This reaction leads to the formation of pink coloured TBA-MDA complex
which is measured at 532nm. 
Procedure:
To 0.1ml of the sample, 2ml of TBA-TCA-HCL reagent (ratio of 1:1:1) was 
added mixed and kept in a water bath for 15minutes. Afterwards the solution was 
cooled and supernatant was removed and the absorbance was measured at 535nm 
against reference blank. The level of lipid peroxidase was given as n moles of MDA
formed/mg protein.
5.3.8.8 HISTOLOGICAL ASSESSMENT[71]
Histological studies of wounded tissues provide accurate diagnosis of level of 
healing of the wound. Histopathology is the microscopical study of tissues for 
pathological alterations. This involves collection of morbid tissues from biopsy or 
necropsy, fixation, preparation of sections, staining and microscopical examination.
Collection of materials
Thin pieces of 3 to 5 mm, thickness were collected from tissues showing gross 
morbid changes along with normal tissue.
Fixation:
Kept the tissue in fixative for 24-48 hours at room temperature
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The fixation was useful in the following ways:
a) Serves to harden the tissues by coagulating the cell protein,
b) Prevents autolysis,
c) Preserves the structure of the tissue, and 
d) Prevents shrinkage 
Common Fixatives: 10% Formalin                            
Haematoxylin and eosin method of staining:
Deparaffine the section by xylol 5 to 10 minutes and remove xylol by 
absolute alcohol. Then cleaned the section in tap water and stained with haematoxylin 
for 3-4 minutes and again cleaned under tap water. Allow the sections in tap water for 
few minutes and counter stained with 0.5% eosin until section appears light pink  (15 
to 30seconds), and then washed in tap water. Blotted and dehydrated in alcohol and
cleared with xylol (15 to 30 seconds). Mounted on a Canada balsam or DPX Moutant 
and kept the slide dry and remove air bubbles.
5.3.8.9 STATISTICAL ANALYSIS
Datas of all the parameters were analyzed using the Graph pad 5.0 software. 
Analysis of Variance (ANOVA); one way ANOVA followed by Tukey’s multiple 
comparison test was performed. The values were expressed as Mean ± SEM. P value
<0.05 was considered as significant.
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6. RESULTS
6.1 EXTRACTIVE YIELD OF EXTRACTS OF Simarouba glauca
Percentage Yield
Coarsely powdered Simarouba glauca leaves were extracted with ethyl acetate 
and aqueous using soxhlet apparatus after deffating with petroleum ether.
The percentage yield of each extract was found to be
• Ethyl  acetate extract (EASG) : 2.85% w/w
• Aqueous extract (AQSG) : 23% w/w
6.2 PRELIMINARY PHYTOCHEMICAL ANALYSIS OF EASG AND AQSG
Table 11: Phytochemical Analysis of Simarouba glauca
Sl.No Phytochemicel constituents EASG AQSG
1 Carbohydrates Positive Positive
2 Glycosides Positive Positive
3 Alkaloids Positive Positive
4 Phenolics Positive Positive
5 Flavonoids Positive Positive
6 Tannins Positive Positive
7 Triterpenoids Positive Positive
8 Saponons Positive Positive
9 Steroids Positive Positive
10 Proteins and amino acids Positive Positive
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6.3 QUANTIFICATION OF TOTAL PHENOL AND FLAVONOIDS
6.3.1 ESTIMATION OF TOTAL PHENOL OF EASG AND AQSG
Table 12: Estimation of total phenolic content of EASG and AQSG
Sample Concentration (µg/ml) Absorbance
Standard 1mg/ml
10 0.0498
20 0.0971
40 0.1907
60 0.2983
80 0.410
100 0.5086
EASG 1000 1.1589
AQSG 1000 0.4472
Figure 5: Total phenolic content of EASG and AQSG
The total phenolic content in EASG was found to be 198.42mg/g of extract 
calculated as Gallic acid equivalent.
The total phenolic content in AQSG was found to be 90.64mg/g of extract 
calculated as Gallic acid equivalent.
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6.3.2 ESTIMATION OF TOTAL FLAVONOID CONTENT OF EASG AND 
AQSG
Table 13 : Quantification of Total Flavonoid Content
Sample Concentration (µg/ml) Absorbance
Standard 1mg/ml
10 0.031
20 0.085
40 0.26
60 0.5026
80 0.776
100 1.053
EASG 1000 0.7046
AQSG 1000 0.1513
Figure 6: Estimation of total flavonoid content of EASG and AQSG
The total flavanoid content in EASG was found to be 77.05mg/g of extract 
calculated as Quercetin equivalent.
The total flavanoid content in AQSG was found to be 26.75mg/g of extract 
calculated as Quercetin equivalent.
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6.4 CHROMATOGRAPHIC SCREENING ANALYSIS
HPTLC study was carried out for the quantification of flavonoids in extract. 
Visualization was performed as done (figure ). After development the plate was 
scanned in densitometer under 254nm and the chromatogram obtained is depicted in 
figure 7. 
Figure 7: Detection of bands:
Table 14: Lists of spots applied on HPTLC plate:
Track number Sample(5µL)
1 SGEA
2 RUTIN
3 QUERCETIN
4 SGAQ
5 GALLIC ACID
6 APIGENIN
7 ANDROGRAHOLIDE
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Figure 8: Chromatogram of Standards, EASG and AQSG
Chromatogram of EASG(5µl)                      Chromatogram of RUTIN (5µl)
Chromatogram of  QUERCETIN (5µl)         Chromatogram AQSG (5µl)
Chromatogram of GALLIC ACID (5µl)        Chromatogram of APIGENIN (5µl)
Results
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Chromatogram of ANDROGRAPHOLIDE (5µl)
Figure 9: 3D Display of Standards, EASG and AQSG
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6.4.1 Quantification of QUERCETIN and GALLIC ACID in EASG and AQSG 
by using HPTLC
Table 15:Amount of QUERCETIN in EASG
Volume 
applied (µl)
Concentration 
(µg/ml) Area
Amount of 
Quercetin 
(µg)
% of 
Quercetin
In 100mg of  
extract
5 500 11238 2.77 0.5
Table 16: Amount of GALLIC ACID in AQSG
Volume 
applied (µl)
Concentration 
(µg/ml) Area
Amount of 
Gallic acid 
(µg)
% of gallic 
acid
In 100mg 
of  extract
5 500 18840.3 1.87 0.36
Results
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6.5 IN VITRO ANTIOXIDANT ACTIVITY OF EASG AND AQSG
6.5.1 DPPH RADICAL SCAVENGING ACTIVITY
Table 17: Percentage inhibition and IC50 values of DPPH radical by Quercetin
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 (µg/ml)
1 5 66.58
2.989
2 10 74.34
3 15 80.58
4 20 87.48
5 25 94.56
6 30 99.38
Fig 10: DPPH radical scavenging activity of Quercetin
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Table 18: Percentage inhibition and IC50 values of DPPH radical by EASG
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 (µg/ml)
1 10 42.67
13.22
2 15 46.55
3 20 55.10
4 25 60.6
5 50 76.9
6 100 91.40
Fig 11: DPPH radical scavenging activity of EASG
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Table 19: Percentage inhibition and IC50 values of DPPH radical by AQSG
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 
(µg/ml)
1 10 26.69
17.77
2 15 43.89
3 20 50.12
4 25 59.67
5 50 69.77
6 100 91.36
Fig 12: DPPH radical scavenging activity of AQSG
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6.5.2 TOTAL ANTIOXIDANT ACTIVITY BY ABTS RADICAL CATION 
ASSAY
Table 20 : Percentage inhibition of ABTS radical by Quercetin
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 
(µg/ml)
1 0.25 70.08
0.1142
2 0.5 75.22
3 0.75 79.62
4 1.0 85.88
5 1.25 91.9
6 1.75 98.85
Fig 13: ABTS radical scavenging activity of Quercetin
0.0 0.5 1.0 1.5 2.0
60
70
80
90
100
110
Concentration (µg/ml)
%
 in
h
ib
it
io
n
Results
Department of Pharmacology Page 82
Table 21: inhibition and IC50 values of ABTS radical by EASG
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 
(µg/ml)
1 1 53.61
1.160
2 2 57.41
3 3 61.63
4 4 71.18
5 5 76.92
6 10 97.37
Fig 14: ABTS adical scavenging activity of EASG
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Table 22: inhibition and IC50 values of DPPH radical by AQSG
Sl.No Concentration (µg/ml)
Percentage 
inhibition
IC 50 
(µg/ml)
1 1 49.64
1.429
2 2 55.72
3 3 57.06
4 4 59.46
5 5 62.00
6 10 78.18
Fig 15: ABTS radical scavenging activity of AQSG
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6.6 ANTI MICROBIAL ACTIVITY OF EASG and AQSG
Table 23: Zone of inhibition for Gram +ve organisms
Organism Standard (mm) AQSG(mm) EASG (mm)
Bacillus subtilis 12 8 15
Micrococcus luteus 10 8 13
Staphylococcus albus 11 11 15
Bacillus lentus 21 7 15
Staphylococcus 
aureus
12 11 14
Figure 16: Zone of inhibition for Gram +ve organisms
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Table 24: Zone of inhibition for Gram –ve organisms
Organism Standard (mm) AQSG (mm) EASG (mm)
Corynae bacterium 30 10 13
E.coli 12 8 12
Klebsella 12 8 14
Pseudomonas 13 10 12
V.cholera 34 8 14
Figure 17: Zone of inhibition for Gram –ve organisms
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Antifungal activity of EASG and AQSG
Table 25: Antifungal activity of EASG and AQSG
organism
Standard 
(mm)
AQSG (mm) EASG(mm)
Candida albicans 15 10 11
Aspergillus 
paraticus
15 6 10
Aspergillus 
fumigatus
25 7 10
Monascus 
purpureus
28 8 10
Aspergillus niger 27 6 9
Figure 18: Antifungal acitivity of EASG and AQSG
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6.6.1 MINIMUM INHIBITORY CONCENTRATION OF EASG AND AQSG
Table 26: MIC values of EASG and AQSG
MIC value
Staphylococcus 
albus (µg/ml)
Coryne bacterium
(µg/ml)
Candida albicans
(µg/ml)
EASG 62.55 125 62.5
AQSG 125 125 250
Figure 19: MIC of EASG and AQSG
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6.7 DETERMINATION OF IN VITRO CELL VIABILITY ASSAY ON 
CULTURED     FIBROBLAST CELLS
Table 27: Percentage cell viability of EASG against MTT assay on Fibroblast
Sl. No
Name of
Test sample
Test Conc.
( µg/ml)
% Cytotoxicity
CTC50
( µg/ml)
1
EASG
62.5
125
250
500
1000
1.52±0.7
8.27±4.6
11.57±4.2
19.99±1.3
24.27±1.9
>1000
Figure 20: Cytotoxic properties of EASG
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Table 28: Percentage cell viability of AQSG against MTT assay on Fibroblast
Sl. No
Name of
Test sample
Test Conc.
( µg/ml)
% 
Cytotoxicity
CTC50
( µg/ml)
1
AQSG
62.5
125
250
500
1000
8.94±2.3
13.45±2.0
16.57±3.9
22.00±0.9
71.33±0.7
785.00±5.0
Figure 21: Percentage cell viability of AQSG
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Figure 22: Cytotoxic properties of of EASG and AQSG
CONTROL Fibroblast
EASG 1000 (µg/ml) EASG 500 (µg/ml)                                        
AQSG 500 (µg/ml)                              AQSG 1000 (µg/ml)
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6.8 PHARMACOLOGICAL STUDIES
6.8.1 EVALUATION OF WOUND HEALING EFFECT OF EASG AND AQSG 
IN EXCISION WOUND MODEL 
Figure 23: Percentage wound contraction on Excision wound model
On 1st day
Control          Simple ointment base   Standard                 EASG                  AQSG
After treatement-4th day
Control          Simple ointment base  Standard                 EASG                  AQSG
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6.8.1.1 PERCENTAGE WOUND CONTRACTION
Table 29: Percentage wound contraction in excision wound model
3rd day (%) 5th day (%) 7th day (%) 9th day (%) 11th day (%) 14th day (%)
Control 7.15±0.1784 20.93±0.0333 46.37±0.1406 65.36±0.1030 72.35±0.0482 80.37±0.0409
Simple 
ointment
7.933±0.0494 21.10±0.0365 49.12±0.3073 69.22±0.0860 75.12±0.3073 84.22±0.3742
Standard 13.33±0.0760 30.52±0.0307 60.08±0.0477 79.66±0.0400 95.20±0.0516 99.92±0.0374
EASG
ointment
12.28±0.1014 28.18±0.0600 55.32±0.0600 73.46±0.0400 82.25±0.0341 94.26±0.0509
AQSG
ointment
19.30±0.0966 26.17±0.0494 50.60±0.7746 70.96±0.0748 79.22±0.0477 91.28±0.0886
Figure 24: Effect of EASG and AQSG on % wound contraction in excission  
wound model
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6.8.2 EVALUATION OF WOUND HEALING EFFECT OF EASG AND AQSG 
IN BURN WOUND MODEL
Figure 25: Percentage wound contraction in burn wound model
On 3rd day
Control     Simple ointment base Standard        EASG              AQSG                                        
After treatment 21st day
Control      Simple ointment base Standard            EASG           AQSG                                        
                                                                                                                                                    Results
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Table 30: Percentage wound contraction in burn wound model
3rd 5th 7th 9th 11th 13th 15th 17th 19th 21st
Control 4.19±0.1934 9.12±0.0945 15.01±0.0786 22.13±0.0113 34.42±0.0678 42.12±0.0345 53.02±0.0224 62.02±0.058 76.98±0.0401 79.95±0.0763
Simple 
ointment
5.29±0.2457 10.65±0.1232 16.73±0.0763 24.43±0.0558 35.32±0.0213 44.67±0.0600 56.65±0.0432 68.22±0.0766 79.17±0.0494 84.18±0.0401
Standard 13.28±0.4567 19.67±0.0365 26.34±0.0201 34.87±0.0976 46.67±0.0374 58.89±0.0558 70.12±0.0881 79.45±0.0111 88.30±0.0966 96.62±0.0600
EASG 
ointment
11.07±0.9661 16.72±0.0601 21.57±0.0374 30.45±0.0453 41.24±0.0456 51.90±0.0112 62.32±0.0122 73.12±0.0866 80.18±0.0600 91.32±0.0600
AQSG
ointment
10.34±0.1014 15.52±0.0491 20.12±0.0600 29.02±0.0432 39.78±0.0345 48.92±0.0866 60.34±0.0409 71.02±0.0374 79.46±0.0400 87.47±0.0881
All values are expressed as mean ± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all groups compared with control; dP<0.001, 
eP<0.01, fP<0.05 when  all groups compared with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
Fig 26: Effect of EASG and AQSG on % wound contraction in Burn  wound model
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6.8.3 EVALUATION OF WOUND HEALING EFFECT IN  INFECTED EXCISSION 
WOUND MODEL
Figure 28: Percentage wound contraction iin infected excision  wound model
On3rd  day
                    
  Control    Simple ointment base      Standard          EASG              AQSG
After treatment -21st dat
                        
        Control      Simple ointment base       Standard            EASG                  AQSG                                        
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Table 31: Percentage wound contraction in infected excision wound model
3rd 5th 7th 9th 11th 13th 15th 17th
Control 5.01±0.0333 11.24±0.4012 20.12±0.0900 29.03±0.0178 36.32±0.0881 56.34±0.0218 69.17±0.7438 72.65±0.0966
Simple 
ointment
5.67±0.0760 12.28±0.1030 21.43±0.0600 29.95±0.0307 37.32±0.0561 59.41±0.1013 72.43±0.0345 76.28±0.0669
Standard 13.33±0.0966 19.98±0.1406 29.93±0.0103 35.89±0.0775 44.76±0.0760 67.30±0.0966 79.65±0.0865 88.17±0.0494
EASG
ointment
11.933±0.172 17.15±0.0365 26.76±0.0860 33.14±0.0516 42.01±0.0365 60.67±0.0498 73.12±0.0600 84.18±0.0600
AQSG
Ointment
9.87±0.0400 16.32±0.0302 24.67±0.0482 30.22±0.0776 40.45±0.0365 59.87±0.0748 71.37±0.0881 81.46±0.0400
All values are expressed as mean ± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all groups compared with control; 
eP<0.01, fP<0.05 when  all groups compared with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
Figure 27: Effect of EASG and AQSG on % wound contraction in infected  excision  wound model
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6.9 EPITHELIALIZATION STAGES OF WOUND HEALING
Table 32: Epithelialization stages of excision, burn and infected excision wound 
models
Group Excision wound Burn wound
Infected burn 
wound
Control 16.67±0.3333 24.83±0.3073 25.00±0.6325
Simple 
ointment
15.17±0.3073c 24.07±0.2108ns 23.33±0.2108c
Standard 11.00±0.2882ad 19.83±0.3073ad 19.83±0.3073ad
EASG 
ointment
14.00±0.2582agns 21.07±0.2108adg 21.67±0.2167adg
AQSG
ointment
14.75±0.2882bgns 21.50±0.2236adns 22.83±0.3073afg
All values are expressed as mean ± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when 
all groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups 
compared with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups 
compared with Standard.
Figue 28: Effect of EASG and AQSG on epithelialization stages in excision 
wound model
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Figure 29: Effect of EASG and AQSG on epithelialization stages in burn  wound 
model
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Figue 30: Effect of EASG and AQSG on epithelialization stages in infected 
excission wound model
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6.10 TENSILE STRENGTH
Table 33: Tensile strength of excision, burn and infected excision wound models
Group
Excision 
wound (g)
Burn wound 
(g)
Infected burn 
wound (g)
Control 336.4270 319.4820 321.4570
Simple 
ointment
412.1450 322.3680 347.6800
Standard 1019.4650 1133.3490 1025.3870
EASG ointment 917.0040 890.9870 901.1380
AQSG
ointment
816.6840 785.1340 822.3870
6.11 ESTIMATION OF HYDROXYPROLINE
Table 34: Hydroxy proline levels in three wound models. Values are expressed as 
µg/g of tissue.
Group
Excision 
wound
Burn wound
Infected burn 
wound
Control 37.67±2.704 42.50±3.686 41.67±1.994 
Simple 
ointment
40.00±3.152
ns
44.33±2.951
ns
43.17±2.315
ns
Standard 82.00±3.088
ad
81.00±4.041
ad
80.17±2.798
ad
EASG 
ointment
70.83±2.903
adns
71.83±2.120
adns
70.50±3.125
adns
AQSG
ointment
64.33±2.431
adh
61.67±2.813
beh
70.33±2.152
adns
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 31: Effect of EASG and AQSG on Hydroxy proline level in  excision  wound 
model
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Fig 32: Effect of EASG and AQSG on Hydroxy proline level in Burn  wound 
model
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Fig 33: Effect of EASG and AQSG on Hydroxy proline level in infected  excision  
wound model
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6.12 ESTIMATION OF HEXOSAMINE
Table 35: Hexosamine levels in three wound models. Values are expressed as 
µg/mg of protein
Group
Excision 
wound
Burn wound
Infected burn 
wound
Control 78.83±1.778 64.00±1.317 81.67±1.145
Simple 
ointment
89.83±1.600c 74.83±1.08ns 91.67±0.8819c
Standard 138.2±0,9458ad 128.2±0.9458ad 129.5±1.176ad
EASG 
ointment
122.8±0.9458adg 114.5±1.335adg 123.7±1.145adh
AQSG
ointment
114.4±1.358adg 106.2±1.014adg 119.8±1.352adg
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 34: Effect of EASG and AQSG on Hexosamine level in  excision  wound 
model
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Fig 35: Effect of EASG and AQSG on Hexosamine level in Burn  wound model
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Fig 36: Effect of EASG and AQSG on Hexosamine level in infected  excision  
wound model
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6.13 ESTIMATION OF URONIC ACID
Table 36: Uronic acid levels in excision, burn and infected excision wound 
models. Values are expressed as µg/mg tissue
Group
Excision 
wound
Burn wound
Infected burn 
wound
Control 19.00±0.3651 15.83±0.6009ns 17.50±0.7638ns
Simple 
ointment
20.67±0.5774ns 20.00±0.5774c 23.33±1.054c
Standard 52.50±0.7638ad 51.50±0.7638ad 55.50±0.4282ad
EASG 
ointment
45.50±0.7638adg 45.50±0.4285adg 48.50±0.7638adg
AQSG
ointment
40.83±0.6009adg 39.83±0.4773adg 41.83±0.4773adg
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 37: Effect of EASG and AQSG on Uronic acid level in excision  wound model
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Fig 38: Effect of EASG and AQSG on Uronic acid level in infected Burn wound 
model
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Fig 39: Effect of EASG and AQSG on Uronic acid level in infected excision 
wound model
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6.14 INVIVO ANTIOXIDANT ACTIVITY
6.14.1 ESTIMATION OF TOTAL PROTEIN
Table 37: Effect of EASG and AQSG on total protein in skin tissue, values 
expressed in mg/g of tissue
Group
Excision 
wound
Burn wound
Infected burn 
wound
Control 46.00±0.9661 41.33±0.7149 45.00±0.5774
Simple 
ointment
50.83±1.014b 45.17±0.6009c 48.67±0.4216c
Standard 72.50±0.7688ad 68.50±0.7638ad 68.17±0.6009ad
EASG 
ointment
64.17±1.195adg 57.33±0.8433adg 58.67±0.8208adg
AQSG
ointment
60.00±0.5774adg 51.50±0.9916fdg 53.83±0.4773adg
All values are expressed as mean ± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when 
all groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups 
compared with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups 
compared with Standard.
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Fig 40: Effect of EASG and AQSG on on Total Protein  level in  excision  wound 
model
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Fig 41: Effect of EASG and AQSG on Total Protein  level in Burn  wound model
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Fig 42: Effect of EASG and AQSG on Total Protein  level in infected  excision  
wound model
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6.14.2 Effect of EASG AND AQSG on In vivo antioxidants of wound tissues of 
excision wound model.
Table 38: Effect of EASG AND AQSG on In vivo antioxidants of wound tissues 
of excision wound model
Groups
Antioxidant enzymes
SOD (unit/mg 
protein)
CAT ( μmol
of H2O2
consumed/min/ 
mg
protein)
GSH
(Glutathione
μg/mg)
LPO (nmol of 
MDA/mgprotei
n
Control 0.48±0.0358 12.70±0.7080 7.16±0.4282 24.50±1.765
Only simple 
ointment
0.60±0.0174ns 14.65±0.2592c 8.16±0.7032ns 24.00±1.265 ns
Standard 2.26±0.1621a,d 21.30±0.5228a,d 13.17±1.352a,c 9.167±1.302 a,d
EASG 
ointment 1.55±0.0428
a,d,g 19.05±0.3334a,d,i 11.83±1.014c,ns 13.83±1.721 a,d,ns
AQSG
ointment 1.183±0.1046
a,e,g 17.17±0.2940a,e,g 11.67±0.7601c,ns 15.50±1.088 a,d,ns
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 43: Effect of EASG and AQSG on SOD level in excision wound model
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Fig 44: Effect of EASG and AQSG on CAT level in excision  wound model
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Fig 45: Effect of EASG and AQSG on GSH level in excision wound model
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Fig 46: Effect of EASG and AQSG on LPO level in excision  wound model
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6.15.2 Effect of EASG and AQSG on In vivo antioxidants of wound tissues of 
Burn wound model
Table 39: Effect of EASG AND AQSG on In vivo antioxidants of wound tissues 
of Burn wound model
Groups
Antioxidant enzymes
SOD(unit/min/
mg protein)
CAT ( μmol
of H2O2
consumed/min/ 
mg
protein)
GSH
(Glutathione
μg/mg)
LPO (nmol of 
MDA/mgprotein
Control 0.39±0.0281 12.42±0.7350 7.5±0.4282 25.67±1.626
Only simple 
ointment
0.54±0.0199 ns 12.67±0.8819ns 8.66±0.6146ns 23.83±0.8333ns
Standard 2.65±0.2125a,d 20.50±1.176b,e 13.50±0.8466a,c 9.50±1.176a,d
EASG 
ointment
1.55±0.078adg 19.67±1.476b,e,ns 10.33±0.6667c,ns 12.17±0.9804a,d,ns
AQSG
ointment
1.13±0.087adg 18.33±1.978c,f,ns 10.63±0.5578c,ns 13.50±0.7638a,d,ns
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 47: Effect of EASG and AQSG on SOD level in burn wound model
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Fig 48: Effect of EASG and AQSG on CAT level in burn wound model
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Fig 49: Effect of EASG and AQSG on GSH level in burn wound model
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Fig 50: Effect of EASG and AQSG on LPO level in burn wound model
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6.15.3 Effect of EASG AND AQSG on In vivo antioxidants of wound 
tissues of Infected excision wound model
Table 40: Effect of EASG and AQSG on In vivo antioxidants of 
wound tissues of Infected excision wound model
Groups
Antioxidant enzymes
SOD(unit/min/
mg protein)
CAT ( μmol
of H2O2
consumed/min/ 
mg
protein)
GSH
(Glutathione
μg/mg)
LPO (nmol of 
MDA/mgprotein
Control 0.456±0.0395ns 12.50±0.7638 7.83±0.6009 28.17±2.056
Only simple 
ointment
0.54±0.0423c 13.17±0.9458ns 8.667±0.6146ns 22.33±0.8433c
Standard 2.533±0.2231a,d 21.50±1.057a,d 11.83±0.7923b,f 10.50±0.7638a,d
EASG ointment 1.49±0.0521a,d,g 19.50±1.0a,e,ns 10.83±0.6009c,ns 12.83±1.014a,d,ns
AQSG
ointment
1.25±0.0600 a,e,g 18.17±1.138b,f,ns 10.67±0.5578c,ns 14.00±1.00a,d,ns
All values are expressed as mean± S.E.M; (n=6)  aP<0.001, bP<0.01,cP<0.05, when all 
groups compared with control; dP<0.001, eP<0.01, fP<0.05 when  all groups compared 
with Simple ointment; gP<0.001, hP<0.01, iP<0.05, when all groups compared with 
Standard.
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Fig 51: Effect of EASG and AQSG on SOD level in infected excission wound 
model
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Fig 52: Effect of EASG and AQSG on CAT level in infected excision wound 
model
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Fig 53: Effect of EASG and AQSG on GSH level in infected excision wound 
model
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Fig 54: Effect of EASG and AQSG on LPO level in infected excision wound 
model
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6.16 HISTOPATHOLOGICAL EVALUATION 
6.16.1 Histopathological evaluation of excision wound model.
Figure 55: Group 1- Control
10X                                            40X
The section of the skin and epidermis shows incomplete healing with less 
epithelialization and lesser collagen formation indicated the incomplete wound 
healing. remodeling, granulation tissue and dispersed inflammation cells were 
observed in this group. 
Figure 56: Group 2- Simple ointment base
10X                                       40X
Section of the skin and epidermis shows proliferation of fibroblasts and few 
macrophages and plasmacells with with infilteration of large number of lymphocytes, 
microphages and a few neotrophils. Dermis also shows mild edema.
Results
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Figure 57: Group 3- Standard
10X                                   40X
Section of the epidermis shows Re-epithelialisation with the proliferation of 
fibroblastgs and few lymphocytes in the sub epithelium with thin walled congested 
blood vessels. Mature connective
tissue and a few capillaries with a thick epidermal lining at the periphery of the 
wound were observed
Figure 58: Group 4- EASG treated
10X          40X
Section of the epidermis shows Re-epithelialization with the proliferation of 
fibroblasts, of dense fibrous tissue and blood capillaries was observed. Few 
macrophages were also present.
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Figure 59: Group 5- AQSG treated
10X                                           40X
Section of the epidermis shows Re-epithelialization with the proliferation of 
fibroblasts, of dense fibrous tissue and blood capillaries was observed. Few 
macrophages were also present. 
6.16.2Histopathological evaluation of Burn wound model
Figure 60: Group 1-Control
10X                                              40X
Section shows marked proliferation of angioblasts and fibroblast with infilteration of 
large number of lymphocytes, microphages and a few neotrophils
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Figure 61: Group 2- Simple ointment base
10X                                           40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts, scattered lymphoplasmacytic infiltrates and thin 
walled congested vessels (Scar)
Figure 62: Group 3- Standard
10X                                      40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts and blood vessels (Scar).
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Figure 63: Group 4- EASG
10X                                         40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts and thin walled  vessels (Scar).
Figure 64: Group 5- AQSG
10X                                       40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts and thin walled vessels (Scar).
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6.16.3Hisopathological evaluation of Infected excision wound model
Figure 65: Group 1- Control
10X                                            40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION, one focal 
shows surface ulceration. Dermis shows proliferation of fibroblasts and thin walled 
vessels and scattered lymphocytes and few neutrophils seen in the section studied.
Figure 66: Group 2- Simple Ointment Base
10X                                             40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION with one 
area shows horn cyst. Dermis shows proliferation of fibroblasts, scattered 
lymphocytic infiltrates and thin walled vessels.
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Figure 67: Group 3- Standard
10X                                           40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts, scattered lymphoplasmacytic infiltrates, few 
neutrophils and thin walled vessels with extravasated rbc’s.
Figure 68: Group 4- EASG
10X                                               40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts and thin walled vessels.
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Figure 69: Group 5- AQSG
10X                                           40X
Section shows skin and the epidermis shows RE EPITHELIALIZATION. Dermis
shows proliferation of fibroblasts, thin walled vessels and few scattered inflammatory 
infiltrates.
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7. DISCUSSION
Wound is a clinical entity and is as old as mankind, often considered as major 
problem in clinical practice.  Each year, millions of people experience burns, suffer 
from chronic wounds, or have acute wounds that become complicated by infection, 
dehiscence or problematic scarring. Wounds are normally resolved in a few days, but 
chronic wounds represent a major burden because of economic and social factors. 
There by, the search for new agents is ongoing and natural products become a great 
target. Individual factors such as stress or diabetes can cause delays in the healing 
process or increase the risk of infection in the wound. Due to unawareness of the 
society this may lead to chronic diseases which may damage the other organs. 
Impaired wound healing can result into severe morbidity leading to long 
hospitalization of patients. States (US) population, which results in a significant 
economic burden estimated to be nearly 2–4% of the health budgets.[85]    
Simarouba glauca or the paradise tree has a long history in herbal medicine in
various countries. The leaves and bark of Simarouba have long been used as a natural 
medicine in tropics. The bark and leaf extract of Simarouba is well known for its 
different types of pharmacological properties such as haemostatic, antihelmenthic, 
antiparasitic, antidysentric, antipyretic and anticancerous.  Externally it is used for 
wound and sores. The major active constituents are Quassinoids namely, 
Ailanthinone, Glaucarubinone, Holocanthone, Dehydroglaucarubinone, 
Benzoquinone, Canthin, Glaucarubine, Glaucarubolone, Simarubin, Melianone, 
Simaroubidin, Simarolide, Sitosterol, Tirucalla and Flavonoids.[41] Since Simarouba 
glauca have not been studied for its Wound healing activity, the present study was 
aimed to evaluate the wound healing potential of ethylacetate and aqueous extracts of 
SG in different wound models of rats.
Phytochemical screening of EASG and AQSG were performed and the results 
revealed the presence of carbohydrates, saponins, flavonoids, alkaloids, triterpenoids, 
glycosides, steroids, tannins, proteins and amino acids. The main attraction of the 
phytochemical was the presence of phenols and flavonoids which was concluded by 
the colorimetric estimation of these constituents in the extract.
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Inorder to justify and quantify the presence of flavonoids, the extract was 
subjected to HPTLC screening against marker compounds such as, Gallic acid, 
Quercetin, Rutin and Apigenin.
Flavonoids are coming under the category of polyphenols, where its action is 
mainly attributed to anti-inflammatory action. And it provides a symptomatic relief in 
wound and sores. .From the results obtained from HPTLC study, it was found that 
EASG contains Quercetin & AQSG contains Gallic acid as flavonoids. The 
percentage of Quercetin present in 100mg of EASG was found to be 0.5% and 0.36% 
of Gallic acid was present in 100mg of AQSG.
Phytopharmaceuticals are gaining importance in modern medicine as well as 
in traditional system of medicine owing to their therapeutic effect due to the presence 
of phytochemicals such as polyphenols, flavonoids, terpenoids etc. 
Flavonoids are widespread plant secondary metabolites that have shown free 
radical scavenging activity and protection against oxidative stress. Studies were 
revealed that flavonoids are also known to promote the wound healing process mainly 
due to their astringent and antimicrobial properties which appear to be responsible for 
the wound healing and increased rate of epithelialisation.[86] Polyphenols are the 
major plant compounds with antioxidant activity that is mainly due to their redox 
properties which enables them to act as reducing agents, hydrogen donors and singlet 
and triplet oxygen scavengers. Results obtained in the present study revealed that the 
levels of these phytoconstituents were considerable and the total phenol and flavonoid 
content was found to be EASG-198.42mg/g, AQSG-90.64mg/g and EASG extract-
77.05mg/g , AQSG-26.75mg/g respectively.
Antioxidants are compounds that inhibit or delay the oxidation of other 
molecules by inhibiting the initiation or propogation of oxidizing chain reactions. 
They are radical scavengers which protect the human body against free radicals that 
may cause pathological conditions such as ageing, dementia, cancer etc.[87] Therefore 
in the present study, the potential of the EASG & AQSG to serve as antioxidants was 
assayed.
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Free-radicals play an important role in the oxidative damage of biological 
systems. Several complementary methods have been adopted to trap free radicals 
through antioxidant activity, among which DPPH* assay is the most common. The 
effect of antioxidants on DPPH is thought to be due to their hydrogen donating 
ability. The free radical scavenging activity of the extract was estimated by comparing 
the %inhibition of EASG &AQSG with standard Quercetin. IC50 was also calculated 
to determine the amount of extract needed to quench 50% of radicals.  Leaf extracts of 
S. glauca exhibited a dose dependent scavenging activity with IC50 values of 13.22
µg/ml, 17.77 µg/ml respectively for EASG and AQSG. Where the IC50 for standard 
Quercetin was found to be 2.99 µg/ml This low IC50 values implies the much 
stronger scavenging of free radicals than other simaroubaceae members like Ailanthus 
altissima and Brucea amarissima.[45]
The ABTS.+ scavenging assay, which employs a specific absorbance (734 
nm) at a wavelength remote from the visible region and requires a short reaction time, 
can be used as an index that reflects the antioxidant activity of the test samples. The 
presence of specific chemical compounds in the extracts of Simarouba glauca may 
inhibit the potassium persulfate activity and hence reduced the production of 
ABTS•+.[88] Simarouba glauca extracts were found to be effective in scavenging 
radicals and the increase was concentration-dependent.  IC50 value of Quercetin was 
0.1149 µg/ml whereas 1.160 µg /ml and 1.429 µg/ml for EASG and AQSG 
respectively. This shows that Simarouba glauca extract presents a good ability to 
scavenge the ABTS radical. The antioxidant activities against ABTS or DPPH were 
correlated with the concentration, chemical structures, and polymerization degrees of 
organ antioxidants.
Thus from the result obtained it could be concluded that EASG & AQSG 
shows a good antioxidant activity which might be attributed to the presence of 
phytochemicals such as polyphenols and flavonoids.
The anti microbial study was carried out for  ethyl acetate and aqoues extract 
of Simarouba glauca against different strain of bacteria (5 Gram + ve and 5 G – ve) 
and fungai (5 strains), that are known to cause infection in human and plants, by disc 
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diffusion method at 200µg/disc. The ciprofloxacin 10µg/disc and fluconazole 
10µg/disc were used as standard for bacteria and fungi respectively.[89]
The standard ciprofloxacin and fluconazole was found to have significant 
antimicrobial activity against bacteria and fungi respectively. The various zones of 
inhibition were observed from all the extracts against various strains. Among the 
extracts the EASG of Simarouba glauca was observed to have significant 
antimicrobial activity than that of AQSG. The zone of inhibition was observed from 
both Gram +ve and Gram –ve bacteria and fungal strains .The maximum zone of 
inhibition (15mm) was found in EASG of Simarouba glauca against B.lentus and
Staphylococcus albus for the Gram +ve organisms. And for Gram –ve organisms the 
maximum zone of inhibition (14mm) was found in EASG against Klebsella and 
V.cholera.  
Both the extracts showed anti fungal activity. The anti fungal activity was 
observed maximum in EASG. Among all, the zone of inhibition was found to be 
maximum for Candida albicans (11mm).
Minimum Inhibitory Concentration (MIC) is defined as the highest dilution or 
least concentration of the extracts that inhibit growth of organisms. Determination of 
the MIC is important in diagnostic laboratories because it helps in confirming 
resistance of microorganism to an antimicrobial agent and it also monitors the activity 
of new antimicrobial agents.[90][91]
For bacterial MIC study, EASG showed least MIC value i.e. 62.55µg/ml 
against S. albus while MIC value of AQSG  was 125µg/ml against S. albus. Whereas 
in case of Coryne bacterium the least MIC value for both the extracts EASG and 
AQSG was found to be 125µg/ml. In the MIC study of fungal strain EASG showed
least MIC value i.e. 62.5µg/ml against Candida albicans. While in case of AQSG the 
observed MIC value was 250µg/ml.
The ability of the cells to survive a toxic insult has been the basis of most 
cytotoxicity assays. This assay is based on the assumption that dead cells or their 
products do not reduce tetrazolium. The assay depends both on the number of cells 
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present and on the mitochondrial activity per cell.[64] The IC50 value after treatment 
with EASG and AQSG was found to be greater than 1000µg/ml, and785.00±5.0 
respectively. Therefore both EASG and AQSG were found to be nontoxic to human 
dermal fibroblast cells since it did not affect the cellular activity of fibroblast cells 
even at high concentration.
Extracts of leaves of of Simarouba glauca demonstrated wound healing 
properties comparable with that of antibiotic standard. Animals in the untreated group 
showed some degree of healing. As earlier suggested, healing in this untreated group 
may be due to self-immunity. It is important to note that throughout the period of 
wound treatment, the extracts did not cause irritation or pain to the animals as the rats 
neither show any signs of restlessness nor scratching/biting of wound site when the 
extracts were applied.
In this investigation three models were used to assess the effect of the EASG 
and AQSG extracts as applied topically. The plant may have a beneficial influence on 
the various phases of wound healing like fibroplasias, collagen synthesis, and wound 
contraction, resulting in faster healing. The results of the present investigation showed 
that both plant extracts have definite wound healing action.
Extract treated excision wounds showed an increased rate of wound 
contraction, leading to faster healing as confirmed by the increased healed area when 
compared to the control untreated group. The EASG extract was recorded similar 
effectiveness when compared to the group treated with a commercial brand of 
povidone iodine ointment in but the magnitude was lesser than standard.
Burn wound model also showed marked increase in wound healing rate. 
Among the two extract treated groups the EASG group exhibited significant rate of 
wound contraction when compared to AQSG. The standard used here was the silver 
sulfadiazine.
                                                                                                                             
Discussion
Deparment of Pharmacology Page 129
Increased wound contraction rate was also observed in the extract treated infected 
excision wounds, when compared to control. Silver sulfadiazine was used as the 
standard. The rate of healing was more for the EASG treated group.[92]
Measurement of the hydroxyproline could be used as an index for collagen 
turnover. Collagen is a major protein of the extracellular matrix and is the major 
component that ultimately contributes to wound strength. Breakdown of collagen 
liberates free hydroxyproline and its peptides.[24] It was observed that Simarouba 
glauca increased the collagen content of the skin ultimately and contributed to wound 
strength. Previous studies stated that there is a strong correlation between the collagen 
fiber formation and acceleration of wound healing.
Tensile strength was measured to confirm the wound healing activity claimed 
for this plant. The increase in tensile strength of treated wounds may be due to 
increase in collagen concentration and stabilization of the fibers.[93] The extract 
showed significant tensile strength when compared to control animals. Our result 
conforms to the earlier studies that the increase in hydroxyl proline content of the 
granulation tissue in treated animal indicates the presence of higher collagen content 
and its turnover leads to rapid healing with concurrent increase in the tensile strength 
of the treated wounds. An increase in tensile strength of the treated wounds may be 
due to the increase in collagen concentration and stabilization of the fibers. The 
collagen molecules synthesized are laid down at the wound site and become cross 
linked to form fibers. Tensile strength is acquired from both remodeling of collagen 
and the formation of stable intra and intermolecular crosslink.
It was found that hexosamine content increased considerably when EASG and 
AQSG extracts applied topically on a wounded rat. Moreover, Hexosamine, which is 
a ground substratum for collagen synthesis, is known to increase during early stages 
of wound healing and decrease thereafter. A similar trend has been observed in the 
present study in hexosamine content of granular tissues. By correlating hexosamine 
content it can be judged how fast the wound heals. It is important to note that 
hexosamine content will increase during wound healing process and decreases when 
maturation and remodeling phase is attained.[93]
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The glycosaminoglycans are known to stabilize the collagen fibres by 
enhancing electrostatic and ionic interactions with it and possibly control their 
ultimate alignment and characteristic size. Their ability to bind and alter protein-
protein interactions has identified them as important determinants of cellular 
responsiveness in development, homeostasis, and disease. We observed an increase in 
uronic acid content in treated animals than in control.[71][93] An increase in uronic acid 
level in treated animals as compared to control animals represents an enhanced 
synthesis of glycosaminoglycans which is similar to earlier observations. Both 
extracts treated groups showed elevated levels of uronic acid in the three models, 
when compared to the controlled untreated group. In our study, hexuronic acid and 
hexosamine concentrations which are the components of glycosaminoglycans were 
significantly increased with EASG when compared with control indicating 
stabilization of collagen fibres. From all the parameters studied it was found that 
EASG showed significant wound healing activity when compared to AQSG.
An increase in the level of antioxidants was observed in granuloma tissues of 
wound. These antioxidants are known to quench the superoxide radical and thus 
prevent the damage of cells caused by free radicals. There is plenty of evidence to 
suggest that increased production of reactive oxygen species, lipid peroxidation and 
ineffective scavenging play a crucial role in various skin lesions and in modulation of 
fibroblast proliferation.[94] Cutaneous wounding causes a depression in the overall 
antioxidant status making it more vulnerable to oxygen radical attack. All these 
finding indicate that in wound healing antioxidants plays an important role. 
Experimental and clinical lines of evidence suggest that chronic wound undergoes 
substantial oxidative stress by neutrophils-derived oxidants which contribute 
markedly to tissue damage during chronic wound inflammation. Over production of 
reactive oxygen species (ROS) results in oxidative stress thereby causing cytotoxicity 
and delayed wound healing and elimination of ROS could be an important strategy in 
healing of chronic wounds.[95] Therefore, estimation of antioxidants like GSH, SOD, 
and CAT in granulation tissues is relevant because the antioxidants have been 
reported to hasten wound healing by decreasing the free radicals. Our studies on the in 
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vivo antioxidants revealed that EASG and AQSG increased the antioxidant activity by 
enhancing the levels of these antioxidant enzymes, thereby reducing free radicals 
stress, preventing inflammation and oxidative damage, ultimately promoting the 
healing process. During the treatment the anti oxidant levels (like SOD, CAT and 
GSH) of the treated groups was increased whereas, there was a significant reduction 
in the LPO levels. Among the two extract treated groups EASG revealed significant in 
vivo anti oxidant activity when compared to AQSG.
From histopathological studies, it was observed that the phases of wound 
healing occurred in a timely manner. The untreated (control) wound healed slowly 
when compared to the wounds treated with EASG and AQSG. Extracts treated groups 
shows large number of collagen tissue (fibrosis) and neovascularisation with minimal 
inflammatory cells. EASG treated showed near to normal features, collagen tissue 
(fibrosis), and neovascularisation when compared to control group.
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8. CONCLUSION
Wound healing is a complex and continuous process that begins immediately 
after injury, followed by homeostasis, blood clotting, inflammation, proliferation and 
remodeling phases. All these phases can promote or prolong healing by influencing 
external or internal factors including infection sex hormones and nutrition. Delay in
healing process increases the possibility of getting infected, improper recovery, and
formation of unpleasant scar.
The study thus demonstrated the wound healing activity of ethyl acetate and 
aqueous extracts of the leaf of Simarouba glauca and found to be effective in the 
functional recovery of the wound. The extracts promote wound contraction; increases
tensile strength, hydroxyproline, hexosamine and uronic acid of excision, infected 
excision and burn wounds as compared to control group. The result may be attributed 
to the phytoconstituents such as flavonoids and phenolics present in it which may be
due to their individual or cumulative effect that enhanced wound healing and provided 
scientific evidence to the ethnomedicinal futures of Simarouba glauca. These findings
could justify the inclusion of this plant in the management of wound healing.
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